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were tested (n=3). ............................................................................................................................. 162 
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ABSTRACT 
 
Purpose 
Glaucoma is the leading cause for irreversible blindness worldwide. The term 
encompasses several ocular disease subtypes with the same end result, namely 
damage to the optic nerve head, of which primary open-angle glaucoma (POAG) is the 
most common. Despite extensive research, the aetiology and progression of POAG 
remain largely elusive. The development of early diagnostic strategies and more 
effective treatment approaches requires a better understanding of the cellular 
mechanisms involved in POAG.  
 
Problem 
Elevated intraocular pressure (IOP) is a key risk factor for POAG and the focus of all 
current treatment strategies. IOP homeostasis is regulated by the trabecular 
meshwork (TM), a specialised tissue within the anterior chamber of the eye that 
determines the rate of aqueous humour outflow. In POAG, a dysfunctional TM leads 
to elevated IOP and consequently damage to the optic nerve head. To date, the 
processes involved in TM dysfunction remain unclear.  
 
Methodology 
Two studies investigated imbalances in human aqueous humour protein 
concentrations using multiplex immunoassays. Proteins measured included matrix 
metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs), various 
cytokines, and growth factors. Samples from POAG patients were compared to non-
glaucomatous cataract patients and results were correlated to disease descriptors 
including age, IOP, cup-disk-ratio (CDR), Humphrey’s visual field pattern standard 
deviation (PSD), and disease duration since diagnosis. Based on the results from the 
second study, the anti-inflammatory cytokine uteroglobin was selected for in vitro 
investigation using a human TM cell model. TM cells were first characterised using a 
panel of TM marker genes and two functional assays: Dexamethasone-stimulated 
myocilin upregulation and collagen gel contraction. For the latter, contractile (human 
fibroblast) and non-contractile (HeLa) control cell lines were included, and ROCK 
inhibitor Y-27632 was used to inhibit contraction. Subsequently, the collagen gel 
contraction assay was used to investigate the effect of 1 and 2 g/ml uteroglobin on 
TM cell contraction over a period of 96 hours. 
 
Results 
The first study found significantly elevated levels of TIMP1, TIMP2, TIMP4, and MMP2 
concentrations in aqueous humour samples from POAG compared to cataract control. 
Imbalances in MMP/TIMP molar ratios were also determined in POAG, several of 
which correlated with IOP and PSD, but not with other disease descriptors. In the 
second study, several cytokines and growth factors, including uteroglobin, HGF, and 
FLRG, were detected in aqueous humour samples from POAG and cataract control 
patients. Uteroglobin and FLRG concentrations correlated significantly with age in 
POAG but not cataract samples. Furthermore, HGF concentrations resulted in a 
negative correlation with disease duration. Gene expression and 
immunofluorescence experiments using primary TM cells determined expression of 
the uteroglobin receptor LMBR1L but not uteroglobin itself. Treatment of primary TM 
cells with recombinant uteroglobin did not significantly affect cell contraction at the 
concentrations tested. 
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Conclusions 
The differences identified in MMPs, TIMPs, and various cytokine concentrations in 
aqueous humour from POAG patients add to our knowledge on aqueous humour 
imbalances in POAG. The analysis of MMP-to-TIMP ratios showed a shift towards 
increased TIMP levels, suggesting a potential increase in MMP inhibition, which may 
affect extracellular matrix composition and thus contribute to elevated aqueous 
humour outflow resistance. Several of the cytokines reported in the second study 
have not previously been quantified in aqueous humour. Correlations of age with 
uteroglobin and FLRG in POAG may indicate an increased need for anti-inflammatory 
(uteroglobin) or anti-calcification (FLRG) activity in the aging glaucomatous TM. 
While no effect of uteroglobin on TM cell contraction was found in the final study, 
further experiments may elucidate the effects this protein has on TM cell function. 
Specifically, phospholipase A2 activity, tissue transglutaminase activity, and 
phagocytosis assays are required to determine the potential effect of uteroglobin on 
TM cells. Determination of the effects of the aqueous humour proteins quantified in 
this thesis on TM cell behaviour may lead to new insights with regards to TM 
dysfunction in POAG and possibly provide new targets for pharmaceutical 
intervention or result in diagnostic biomarkers for POAG. 
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 LITERATURE REVIEW 
 
1.1 GLAUCOMA – A COMPLEX OPTIC NEUROPATHY 
Glaucoma is the leading cause of irreversible blindness, affecting an estimated 60.5 
million people worldwide in 2010, with a predicted increase to 111.8 million by 2040 
(1), due to the rapid rise in the aging population. In Australia, a prevalence of 3% has 
been reported in people over the age of 49 (2, 3), which equates to approximately 
300,000 individuals. Typically, glaucoma affects peripheral vision first and blindness 
can ensue if left untreated (4). Whilst treatment can slow down or even arrest disease 
progression (5), existing visual field defects are irreversible, making early detection 
critical. The slow, insidious progression of chronic glaucoma, occurring over many 
years, combined with the late appearance of symptomatic visual field defects, means 
that diagnosis often does not occur until the disease has reached an advanced stage, 
and for the same reasons, many cases remain undiagnosed (6, 7). By these later 
stages, central visual acuity and the ability to read are affected, which severely impact 
on a patient’s quality of life (8). Glaucoma therefore presents a considerable burden 
on health care systems (9), particularly due to the chronic nature of the disease, 
requiring life-long treatment and regular clinical reviews. Specifically, a study by the 
Centre for Eye Research Australia (CERA) reported an annual health care cost due to 
glaucoma of AUD 342 million in 2005 (10). As a consequence, efforts have been made 
to introduce population screenings for glaucoma to enable early detection and 
treatment, although the lack of a single, definitive test for glaucoma presents a 
considerable challenge (11, 12). Current research mainly focusses on more reliable 
early diagnosis and improved treatment strategies to lessen the social burden and 
improve patient quality of life. 
Chapter 1 
1.1.1 Definition 
The term glaucoma encompasses a heterogeneous group of ocular diseases with the 
common clinical denominator of progressively degenerating retinal ganglion cell 
(RGC) axons, which leads to a distinct cupping of the optic nerve head and 
characteristic visual field damage (13-15). This common clinical characteristic is 
known as glaucomatous optic neuropathy (GON). Whilst the pathogenesis of GON 
remains unclear, several potential mechanisms leading to RGC degeneration and 
resultant visual field damage have been described in the literature and are outlined 
in section 1.1.3.3. In addition to the uncertain development of glaucomatous damage, 
the numerous glaucoma subtypes present with varied aetiologies, risk factors, 
demographics, symptoms, disease durations, and prognoses and require differing 
treatment strategies (8). For these reasons, correct diagnosis and treatment of 
glaucoma remains a challenge. 
 
1.1.2 Glaucoma subtypes 
The different forms of glaucoma are divided into subcategories, based on the 
morphology of the anterior chamber angle, the age of onset, and whether the disease 
results from an identifiable cause or not (4, 15). This subdivision is summarised in 
Figure 1.1. Whilst intraocular pressure (IOP) is not a defining criterion for glaucoma 
(13), it does play a role in categorising different forms of glaucoma. The existence of 
a clear cause for IOP elevation in association with GON, such as an inflammation, eye 
injury, or steroid treatment, divides the glaucomas into primary and secondary forms. 
The former lacks an identifiable cause, whereas in the latter, the source of increased 
IOP is recognizable. A second subdivision is made based on the status of the 
iridocorneal angle (Figure 1.2). In open-angle glaucoma, the chamber angle is 
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unobstructed (Figure 1.2B), and any increase in IOP cannot be explained by visible 
changes to the anterior chamber. Contrarily, a closed, physically obstructed angle 
blocks aqueous humour outflow at a macroscopic level and is labelled closed-angle 
glaucoma (Figure 1.2C). Although the relevance is disputed (16), a further subdivision 
exists in primary open-angle glaucoma (POAG), depending on the level of IOP. A 
subset of POAG patients do not present with elevated IOP, which has been termed 
normal tension glaucoma (13, 15). Depending on the age of onset, glaucoma subtypes 
can be further classified as congenital, juvenile, or adult onset glaucoma. Among these 
different types of glaucoma, all of which are potentially progressive and can lead to 
blindness (15), POAG is the most common form (14, 17) and will be the focus of this 
review. 
Chapter 1 
 
Figure 1.1 Glaucoma subcategories based on cause, anterior chamber angle 
morphology, and IOP. Figure adapted from (15). 
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Figure 1.2 Iridocorneal angle morphology and aqueous humour outflow pathways 
(yellow arrows). A) Aqueous humour flow in a healthy eye. B) Aqueous humour 
outflow is reduced despite an open iridocorneal angle. C) Angle closure prevents 
Chapter 1 
aqueous humour from passing between the lens and iris into the anterior chamber. 
Image reproduced from (18). 
 
1.1.3 Primary open-angle glaucoma 
1.1.3.1 Definition and clinical assessment 
POAG is a complex, multifactorial disease with a development that remains largely 
elusive. The disease is defined as glaucomatous damage to the optic nerve head in the 
presence of an open iridocorneal angle (Figure 1.2B), with no determinable cause for 
IOP elevation (15). Early POAG diagnosis is critical but also challenging, as the 
diagnosis is often not clear-cut. Due to this uncertainty, regular clinical reviews are 
required to assess whether there is a progression of symptoms necessitating medical 
treatment.  
 
POAG diagnosis is based on the presence of characteristic optic disc cupping, 
corresponding visual field defects, and a thinning of the retinal nerve fibre layer (19). 
Optic disc cupping is assessed by means of the vertical cup-to-disc ratio (CDR). An 
enlarged optic cup results in an increased CDR value and is due to the loss of RGC 
axons. RGC axonal degeneration is also responsible for the thinning of the retinal 
nerve fibre layer, which is measurable by ocular coherence tomography (14). The 
resulting glaucomatous visual field defects can be detected by means of perimetry, 
although functional loss is generally not detectable until at least 20-50% of RGCs have 
been lost (20, 21). A visual field test maps specific locations of damage and provides 
parameters such as mean deviation (MD) and pattern standard deviation (PSD). The 
former compares the mean deviation of a patient’s results to an age-matched 
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normative database, whereas the latter highlights focal variation within the visual 
field of one patient (22). Additional methods can be used to assess visual field defects, 
such as blue-on-yellow perimetry to test loss of colour-contrast sensitivity (23, 24). 
To determine whether the patient is presenting with open- or closed-angle glaucoma, 
the anatomy of the iridocorneal angle is assessed by means of gonioscopic 
examination. As POAG can present without IOP elevation, the diagnosis is made 
irrespective of the pressure measured. 
 
1.1.3.2 Risk factors 
POAG aetiology involves a variety of ocular, systemic, environmental, and genetic risk 
factors. The main risk factors for POAG are advancing age and elevated IOP. A family 
history of POAG and African ethnicity are also strongly associated with an increased 
risk for developing the disease (25). Of these, IOP is the only modifiable risk factor 
and the current focus of all treatment strategies.  
 
It is well known that genetics play an important role in POAG. A first-degree relative 
with POAG increases the risk of developing the disease by ten-fold in comparison to 
the general population (26). However, POAG is a genetically complex and 
heterogeneous disease and the majority of cases are adult onset and not inherited in 
a Mendelian fashion. The use of family linkage studies has revealed causative 
mutations for adult-onset POAG in a number of genes, including myocilin, optineurin, 
and WD repeat domain 36 (reviewed in (27)), yet these only explain up to 10% of all 
POAG cases (28). More recently, genome-wide association studies (GWAS) have 
identified numerous loci associated with POAG. The variants detected in GWAS are 
more common than those described above and present risk alleles for POAG rather 
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than causative mutations (29, 30). The information obtained through GWAS has 
highlighted several cellular pathways that may be involved in POAG pathogenesis, 
such as extracellular matrix (ECM) metabolism, TGF- signalling, and the rhoA/rho-
associated kinase pathway (reviewed in (31)). 
 
Whilst several additional factors have been associated with an increased prevalence 
of POAG, their validity as risk factors is uncertain. Association of gender with the 
prevalence of POAG has been inconsistent (32), yet some meta-analyses of population 
studies have found a higher prevalence in men (1, 33, 34). The validity of myopia as a 
risk factor has been questioned due to the difficulty of detecting GON in myopic eyes 
(35). Further factors that may be associated with a greater risk for POAG include 
diabetes mellitus, arterial hypertension, body mass index, central corneal thickness, 
obstructive sleep apnoea, and atherosclerosis, although these associations are 
uncertain and require further research (reviewed in (8, 27, 36)). 
 
1.1.3.3 Aetiology of primary open-angle glaucoma and the relevance of intraocular 
pressure 
Many mechanisms have been suggested to explain the loss of RGC axons that 
underlies optic nerve head damage, some of which are directly related to elevated IOP. 
These mechanisms include impaired axonal transport, which deprives RGCs of 
neurotrophic factors critical to survival, glial cell activation in response to elevated 
IOP, and hypoxia caused by reduced blood flow at the optic nerve head (reviewed in 
(4, 37, 38)).  
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Elevated IOP has commonly been defined as a pressure that exceeds 21 mm Hg. This 
value represents a purely statistical concept and corresponds to two standard 
deviations above the mean value of 16 mm Hg, assuming a Gaussian distribution (16).  
Elevated IOP was long thought to be a causative factor for POAG but is now considered 
merely a risk factor (15) for two reasons: First, increased IOP does not necessarily 
lead to GON (39). Secondly, GON may present itself in the absence of elevated IOP, 
which is often referred to as normal tension glaucoma (13, 15). Thus, elevated IOP is 
not a defining feature of POAG and IOP-independent mechanisms are likely involved 
in the development of GON, such as ischemia, loss of neurotrophic signalling, and 
neurotoxicity (37, 38).  
 
Although POAG can occur in people with normal IOP, ocular hypertension is a risk 
factor for the development of GON, and the likelihood of developing POAG is increased 
at higher IOP levels (40, 41). Several randomized clinical trials have shown that 
reduction of IOP by means of hypotensive medication, laser therapy, or surgical 
intervention delays the onset and progression of glaucoma (5, 42-44), and lowering 
IOP not only benefits patients with elevated pressures, but also improves outcomes 
for so-called normal tension glaucoma (45, 46). The fact that hypotensive treatment 
benefits these patients suggests that normal tension glaucoma is also linked to IOP 
(15). 
 
Whilst there is consensus that elevated IOP is due to increased aqueous humour 
outflow resistance rather than increased aqueous production (47, 48), the precise 
mechanisms involved in altered outflow resistance remain unclear. Many theories 
exist, which are discussed in section 1.3.2, and elucidating the causes of increased 
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outflow resistance forms a key area of active research in glaucoma. The precise link 
between elevated IOP and optic nerve damage is also yet to be determined. Several 
animal studies have demonstrated that elevation of IOP leads to RGC degeneration 
and optic nerve head damage (49-51), and it is thought that the pressure increase 
causes mechanical changes at the lamina cribrosa, leading to RGC axonal injury and 
death (52). 
 
1.1.3.4 Current treatment strategies 
To date, reduction of IOP remains the only proven treatment strategy for glaucoma 
(8), which is achieved by a range of topical or oral medications, laser trabeculoplasty, 
or incisional surgery, such as trabeculectomy or the placement of a drainage implant 
(reviewed in (53)). The topical treatments available alter IOP by either increasing 
uveoscleral outflow or reducing aqueous humour production. A new class of drugs 
called rho kinase inhibitors, which increase trans-trabecular outflow, have recently 
been approved for clinical use (54). The aqueous humour outflow pathways 
mentioned above are further discussed in section 1.2.2. 
 
1.2 OCULAR ANATOMY AND AQUEOUS HUMOUR DYNAMICS  
1.2.1 Ocular anatomy - an overview 
The human eye is divided into two main compartments: the anterior segment and the 
posterior segment (Figure 1.3). The former consists of the lens and all the structures 
in front of it, whereas the latter comprises all structures that lie behind the lens. The 
anterior segment of the eye is further subdivided into the anterior and posterior 
chamber (Figure 1.3), both of which are filled with aqueous humour. The posterior 
chamber contains the lens and the ciliary body and is separated from the anterior 
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chamber by the iris. The cornea, the anterior face of the iris, the trabecular meshwork 
(TM), and Schlemm’s canal jointly form the anterior chamber (55, 56).  
 
In the posterior segment, the inner surface of the eye, called the fundus, consists of 
the retina, the optic disc, the macula, and the fovea (Figure 1.4). RGCs and their axons 
form the retinal nerve fibre layer, which makes up the innermost layer of the fundus. 
The visual impulses generated by the photoreceptors in the retina are transmitted via 
bipolar cells to the RGCs. The signal is then relayed to the lateral geniculate nucleus 
in the brain via the RGC axons, which leave the eye at the optic disc to form the optic 
nerve. The optic disc is therefore also known as the optic nerve head (57). The base 
of the optic nerve head is formed by a mesh-like, collagenous structure called the 
lamina cribrosa, through which the optic nerve fibres pass as they exit the eye. The 
lamina cribrosa is thought to be the principal site of RGC axonal injury, leading to the 
characteristic optic disc cupping observed in glaucoma (58). 
Chapter 1 
 
Figure 1.3 Anatomy of the human eye – subdivision into anterior and posterior 
segment. The anterior segment is further subdivided into the anterior and posterior 
chamber. Figure reproduced from (55). 
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Figure 1.4 Anatomy of the human eye. Reproduced with permission from Carlson Stock 
Art. 
 
1.2.2 Aqueous humour and the generation of intraocular pressure 
Aqueous humour is the clear fluid secreted by the ciliary body (see Figure 1.4) that 
circulates through the anterior chamber to supply the avascular iris, lens, TM, and 
cornea with nutrients, as well as removing waste from these tissues (Figure 1.2). It 
consists of a complex mixture of organic solutes, ions, and proteins (59-62). In 
addition, the volume of aqueous humour determines IOP, which is critical for eye 
health, maintenance of correct ocular shape, and clear vision. IOP is closely regulated 
through the balance between aqueous humour secretion in the posterior chamber 
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and drainage through the trabecular and uveoscleral pathways (63-66). The majority 
of aqueous humour drains through the trabecular pathway, which involves the TM 
and Schlemm’s canal (67). As aqueous humour secretion is relatively constant and 
pressure-independent up to high levels of pressure, IOP is predominantly determined 
by outflow resistance through the trabecular pathway, which is modulated in order 
to enable IOP homeostasis (47, 68, 69). Whilst it is unclear exactly where and how 
outflow resistance is generated and regulated (47, 48, 70), there is consensus that the 
TM plays a key role in the regulation of IOP (71), which will be discussed in section 
1.3.1.2. 
 
1.2.3 Altered aqueous humour composition in primary open-angle glaucoma 
Aqueous humour contains a vast range of proteins, including many growth factors 
and cytokines, and several studies have shown that the composition of aqueous 
humour is altered in POAG, as detailed below. In most cases, the comparison is made 
to aqueous humour from patients with cataract, as it can be sampled with ease during 
routine cataract surgery. Ideally, aqueous humour from healthy eyes would serve as 
the control, but such sample collection would be unethical. Whilst many studies of 
aqueous humour composition in animal models exist, this review focusses exclusively 
on human aqueous humour. 
 
Due to the low protein concentration in aqueous humour and the small sample 
volumes available for testing, laboratory techniques with high sensitivity are 
preferential for composition analysis, in order to maximise the data generated (72, 
73). Two main approaches have been used to date: mass spectrometry and multiplex 
immunoassay technology. Exploratory studies using mass spectrometry have 
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provided insight into the composition of aqueous humour (74-76) and highlighted 
several proteins with altered abundance in POAG when compared to cataract control 
samples. The proteins identified include ones involved in oxidative stress, apoptosis, 
mitochondrial function, inflammation, metabolism, and proteolysis (77-82), 
highlighting these processes as potentially relevant to POAG pathogenesis. Whilst 
mass spectrometry has allowed researchers to take a global, unbiased view of the 
aqueous humour proteome, the technique’s sensitivity limitations make the detection 
of low abundance proteins (ng/ml and lower), such as cytokines, growth factors, and 
soluble receptors challenging (72). Multiplex immunoassays on the other hand allow 
the simultaneous quantification of dozens of proteins per sample. These assays allow 
the determination of specific protein concentrations, yet the proteins to be tested 
need to be pre-selected, thus resulting in a biased view of the aqueous humour 
proteome. Despite the increased sensitivity compared to mass spectrometry 
techniques, many analytes still escape detection in multiplex immunoassay screens 
(72). 
 
Of the many proteins present in aqueous humour, only a small number have been 
studied in some detail with regards to POAG. Several studies have shown significantly 
increased levels of TGF-2 in POAG aqueous humour compared to non-glaucomatous 
cataract samples (summarised in (83)). The effects of TGF-2 on the TM have been 
investigated extensively and studies have demonstrated a multitude of consequences 
on TM physiology, including increased ECM production, inhibition of ECM 
degradation, and a reduction in TM cellularity (reviewed in (83-85), further discussed 
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in 1.3.2.4). Several ex vivo and in vivo studies have also indicated that elevated levels 
of TGF-2 cause reduced aqueous humour outflow (86-88).  
 
Two further protein families that have been investigated in detail are the matrix 
metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs). MMPs 
are proteolytic enzymes that degrade a variety of ECM molecules. Due to their 
destructive nature, MMP activity requires tight regulation. MMPs are secreted in a 
latent form and require extracellular cleavage of the pro-domain for activation (89). 
In addition, TIMPs reversibly bind to MMPs in a 1:1 stoichiometry to obstruct the 
MMP proteolytic site (90), thus inhibiting their activity. Several members of the MMP 
family and all four known TIMPs are expressed by TM cells and numerous MMPs and 
most TIMPs have been measured in human aqueous humour samples (reviewed 
extensively in (91)). Table 1.1 provides an overview of the reported changes in MMP 
and TIMP concentrations in POAG aqueous humour compared to cataract. 
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Table 1.1 Overview of published data regarding levels of MMPs and TIMPs found in 
human aqueous humour from POAG compared to cataract patients. 
Isoform Status POAG levels (in comparison to cataract) References 
MMP2 Total  Significant (92, 93) 
   Non-significant (94-97) 
 Active  Significant (92, 98) 
   Significant (97) 
MMP3 Total  Non-significant (92, 97) 
 Active  Significant (92) 
 Latent  Significant (93) 
TIMP1 n/a  Significant (92, 93) 
   Non-significant (97) 
TIMP2 n/a  Significant (92-95) 
   Non-significant  (96, 97) 
TIMP3 n/a No data available  
TIMP4 n/a  Significant (92) 
Isoforms where only non-significant changes were reported have been 
excluded from the list. n/a: not applicable. 
 
 
Whilst some previous publications include the calculation of direct MMP-to-TIMP 
ratios (ratio of concentrations measured) (92, 93, 97, 99, 100), none have considered 
the sizeable differences in molecular weight between MMPs and TIMPs. Given that 
MMPs and TIMPs interact at a 1:1 ratio, a stochiometric analysis that includes the 
molecular sizes would provide a more accurate indication of MMP-to-TIMP 
imbalances. Such imbalances are of interest due to the known role of MMPs in outflow 
facility (101) and the reported changes in TM ECM composition. Specifically, it has 
been suggested that the excessive accumulation of ECM material within the TM of 
POAG eyes may be due to imbalanced MMP-to-TIMP ratios (97). 
 
The aqueous humour concentrations of numerous other growth factors and cytokines 
are also altered in POAG, although the effects of these changes on TM function remain 
to be elucidated. Increased levels of IL-8, IL-9, IL-10, IL-12, SAA, INF, INF, TNF, 
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CCL2, and CXCL9 have been reported (102-106), although not all studies were able to 
detect these factors and only some adjusted their p-values to correct for multiple 
testing. On the other hand, IL-6 concentrations are reduced in POAG (103, 107). 
Collectively, these observations have led some researchers to suggest the 
involvement of inflammatory processes in TM dysfunction and POAG (104, 108, 109). 
Other specific proteins present in the aqueous humour that have been investigated in 
relation to POAG include CD44S (110), EPO (111, 112), fibronectin (113), HGF (114), 
myocilin (115), and VEGF (116).  
 
For the most part, it is unclear how these changes in aqueous humour composition 
relate to clinical descriptors of POAG, as few studies have investigated correlations 
extensively. Studies that have assessed correlations have predominantly focussed on 
IOP, medication, and age (95, 96, 103, 104, 107, 117). Changes in protein abundance 
may still be relevant to TM dysfunction, even if they do not differ significantly from 
the concentrations found in cataract control samples. Thus, correlation with clinical 
descriptors offers an additional approach to analysing data gained from aqueous 
humour studies and may provide new insights into relevant disease mechanisms. 
 
1.3 TRABECULAR MESHWORK DYSFUNCTION 
1.3.1 Structure and function of the healthy trabecular meshwork 
1.3.1.1 Trabecular meshwork architecture - an overview 
The TM is a complex, connective tissue located in the iridocorneal angle, between the 
cornea, the sclera, and the iris (Figure 1.2). The anatomy of the TM has been reviewed 
in detail (71, 118). Briefly, the tissue consists of three different structural regions 
(Figure 1.5). As the aqueous humour leaves the eye via the trabecular pathway, it 
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passes through the uveal meshwork, the corneoscleral meshwork, and finally the 
juxtacanalicular tissue (JCT), before entering Schlemm’s canal. Subsequently, the 
aqueous humour drains into the episcleral veins. This fluid movement occurs as bulk 
flow driven by the pressure gradient rather than active transport (118). 
 
 
Figure 1.5 Anatomy of the trabecular meshwork. The trabecular meshwork consists of 
three layers: the uveal meshwork (blue), the corneoscleral meshwork (red), and the 
juxtacanalicular tissue (green). Figure reproduced from (119). 
 
The uveal meshwork is comprised of a network of trabecular beams covered in a thin, 
continuous monolayer of flat TM cells. The beams contain densely packed collagen 
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and elastic fibres and the TM cells are situated such that they bridge the 
intertrabecular spaces and connect adjacent beams. The corneoscleral meshwork, 
which forms the thickest layer of the TM, is made of perforated collagen and elastin 
sheets covered in TM cells. Both the uveal and the corneoscleral meshwork are highly 
porous and thus do not contribute significantly to outflow resistance (reviewed in 
(118, 120)). Instead, they function as a self-cleansing biological filter, responsible for 
clearing cellular debris and reactive oxygen species that could prevent the JCT from 
functioning (71). Unlike the uveal and corneoscleral meshwork, the JCT, which lies 
adjacent to the inner wall of Schlemm’s canal, lacks trabecular beams and instead 
consists of TM cells loosely arranged in a fibrillar ECM forming an irregular network 
(120). The JCT, in combination with the inner wall endothelium of Schlemm’s canal, 
is thought to be the site where outflow resistance is generated (47, 48). 
 
1.3.1.2 Biological properties of trabecular meshwork cells 
The TM has two primary roles: filtration of the aqueous humour and generation of 
outflow resistance. In order to fulfil these responsibilities, TM cells execute a diverse 
range of biological functions (summarized in Table 1.2). Due to their morphology, TM 
cells have often been referred to as endothelial-like cells (121-123). Whilst they do 
exhibit endothelial cell behaviours (see Table 1.2), this description fails to recognise 
many critical aspects of TM cells. Recently, Stamer and Clark published a 
comprehensive review of the TM cell’s diverse biological properties (71), which 
highlighted that TM cells assume behaviours typical of macrophages, fibroblasts, 
endothelia and smooth muscle cells, in order to maintain outflow resistance and 
successfully respond to the wide-ranging stressors experienced by the TM, which 
include phagocytic, mechanical, metabolic, and oxidative stresses.   
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Table 1.2 The diverse biological functions of trabecular meshwork cells correspond to 
different cell phenotypes and behaviour. Table reproduced from (71). 
Phenotype Location Cell behaviour Responsibilities 
Endothelial Uveal/corneoscleral Endothelia 
 
 
 
Macrophage 
Maintain passageway 
patency 
Neutralize reactive oxygen 
species 
Biological filter/ 
phagocytosis 
Immune mediation 
Fibroblastic Juxtacanalicular 
tissue 
Fibroblast 
Smooth muscle 
ECM turnover/tissue repair 
Contractile tone 
Mechanotransduction 
 
 
1.3.1.2.1 Resistance generation 
The TM’s central role is the generation and regulation of aqueous humour outflow 
resistance, in order to maintain IOP within an acceptable physiological range. 
Resistance generation is thought to occur in the JCT, in conjunction with the inner wall 
endothelium of Schlemm’s canal and its basement membrane (47, 48, 124, 125). 
Specifically, the ECM of the JCT has been suggested to play a major role in determining 
aqueous humour outflow resistance (68, 120, 126-128), although other mechanisms 
have been proposed and resistance generation is yet to be fully understood (48, 129). 
The TM ECM and its components, which have been reviewed in detail (68, 118), are 
not static, as the ECM undergoes continuous remodelling to maintain open outflow 
pathways (120). In addition, elevated IOP is sensed in the JCT through mechanical 
stretch, triggering a cascade of events to alter ECM composition and thus outflow 
resistance. These processes, referred to as IOP homeostasis, involve the secretion of 
ECM proteins and their corresponding degradation enzymes (reviewed in (69, 130)). 
One major group of proteinases involved in ECM degradation are MMPs. Several 
MMPs are expressed by TM cells and mechanical stretching, increased pressure, and 
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treatment with specific cytokines can lead to an increase in MMP expression levels 
(91, 130). The importance of MMPs, and thus ECM turnover, in controlling aqueous 
humour outflow was initially demonstrated by treating perfused anterior segments 
with MMPs or agents that stimulate MMP expression, which led to increased aqueous 
outflow. On the contrary, inhibition of MMP activity through the addition of TIMPs 
reduced outflow facility (101). 
 
In addition to ECM composition, cellular contraction is also involved in regulating 
aqueous humour egress and the two are linked through integrin signalling. Thus, 
changes to the ECM are transmitted to the intracellular space and can affect cell 
contraction (131, 132). Both the TM and the JCT contain contractile cells, allowing 
them to alter the geometry of the outflow pathways (129). Specifically, contraction of 
TM cells leads to increased outflow resistance, whereas relaxation enhances aqueous 
humour egress (reviewed in (133, 134)). The contractile state of the ciliary muscle 
and the scleral spur cells (see Figure 1.5) further influence the geometry of the 
trabecular outflow pathways (reviewed in (129, 135)). 
 
1.3.1.2.2 Aqueous humour filtration 
Filtration of aqueous humour is thought to be critical for TM homeostasis, as the 
presence of debris in the JCT could obstruct aqueous humour outflow and prevent 
proper resistance generation (136-138). The TM cells in the uveal and corneoscleral 
meshwork are highly phagocytic (139-142), which allows them to clear cellular 
debris, reactive oxygen species, pigment granules, and pseudoexfoliative material 
present in the aqueous humour (reviewed in (71)). In addition, phagocytosis has been 
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shown to affect the expression of ECM remodelling enzymes (143), suggesting it may 
also play a role in TM ECM homeostasis. 
 
1.3.2 Trabecular meshwork dysfunction in primary open-angle glaucoma 
Aqueous humour outflow resistance is elevated in glaucomatous eyes when 
compared to age-matched controls (144). The cause of increased outflow resistance 
in the TM is still unknown and many theories have been postulated. Rather than 
offering an exhaustive summary of each hypothesis presented in the literature, this 
section provides an overview of mechanisms that have been studied in considerable 
detail and that are relevant to the investigations contained in this thesis. The diverse 
range of processes studied in the field suggests that impaired regulation of outflow 
facility is likely due to a complex combination of changes, both at the cellular and 
tissue level, that lead to TM dysfunction.  
 
Much of the current knowledge on TM cell dysfunction in POAG has come from studies 
using cultured TM cells. To date, no unique genetic marker or feature has been 
determined for TM cells, making identification of TM cells reliant on a combination of 
criteria. Due to a lack of consensus, different laboratories have used varying criteria 
to characterise TM cell cultures in the past, including morphology, the expression of 
various marker genes, corticosteroid induction of cross-linked actin networks 
(CLANs), phagocytic capacity, and Dexamethasone-stimulated myocilin upregulation 
(145-148). Further known cellular responses, as well as a list of positive and negative 
selection markers, are summarised in a recent review by Stamer and Clark (71). The 
lack of consensus for TM cell characterisation in vitro was recently addressed in a 
publication by Keller et al. (149), recommending the use of a panel of marker genes 
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in combination with functional assays, in particular myocilin induction by 
Dexamethasone, which is considered the most reliable assay for functional TM 
characterisation. 
 
1.3.2.1 Reduced trabecular meshwork cellularity 
A gradual reduction in TM cell numbers is part of the aging process in healthy eyes 
(150, 151). Continuous TM cell loss occurs at a similar rate in POAG, but overall 
cellularity is lower than in age-matched controls (152). In addition, a greater number 
of senescent cells has been determined in the glaucomatous TM (153). The loss of TM 
cells leads to areas where trabecular beams are no longer covered, which has been 
suggested to cause the fused trabecular beams observed in eyes with advanced POAG 
(152, 154, 155). It has been hypothesised that reduced cell numbers affect the TM’s 
ability to respond to increased pressure, which TM cells sense through mechanical 
distortion (120). 
 
The mechanisms involved in TM cell death remain unclear. In a recent review, Green 
et al. (156) examined five cell death pathways (apoptosis, autophagy, necroptosis, 
pyroptosis, and immunogenic apoptosis), all of which may contribute to reduced TM 
cellularity, and suggested that immunogenic apoptosis is the most likely, due to the 
involvement of oxidative and ER stress in TM dysfunction. Based on animal studies, it 
has been suggested that phagocytic TM cells may leave the meshwork upon engulfing 
foreign particles, which could also contribute to reduced cellularity (140, 142, 157, 
158). However, subsequent studies using human perfused anterior segments saw 
little to no cell loss in response to phagocytic challenge in single exposure 
experiments (139, 159). 
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1.3.2.2 Abnormal extracellular matrix accumulation in the trabecular meshwork 
The composition of the TM ECM changes with age and POAG (155, 160-162) and 
characteristic structural alterations have been described in the JCT of POAG eyes 
(reviewed in (121, 155)). The quantity of sheath-derived plaques is significantly 
increased in POAG compared to age-matched controls (160, 161). Whilst the amount 
of plaque material in the JCT has been correlated with severity of optic nerve damage 
in POAG, no correlation was found with IOP (163), which may suggest that these 
changes are a consequence rather than a cause of POAG (135). In contrast to many 
ECM components, the amount of hyaluronic acid found in the TM is reduced in POAG 
(164). Treatment of TM cells with hyaluronic acid in vitro stimulated MMP2 and 
MMP9 expression (165). Inhibition of hyaluronic acid synthesis reduced outflow 
facility in perfused human anterior segments and led to decreased levels of ECM 
proteins fibronectin and versican (166, 167). Thus, the reduced hyaluronic acid levels 
seen in POAG may contribute to abnormal ECM accumulation. Some researchers have 
proposed that the ECM changes seen in the glaucomatous TM may be described as 
fibrosis (132, 168-170) and many have hypothesized that elevated outflow resistance 
is due to changes in the TM ECM. A key finding that supports the latter is that 
perfusion of anterior eye segments with MMPs increases outflow facility (101). 
 
1.3.2.3 Altered trabecular meshwork cell contraction state 
The discovery that TM cells are contractile (171) and that TM cell tone affects outflow 
facility (134) led to another hypothesis; increased outflow resistance in POAG may be 
due to an elevated TM cell contraction state, leading to increased rigidity and reduced 
outflow facility. Chemical disruption of the actin cytoskeleton leads to increased 
outflow facility (133, 172), an observation that supports the contraction hypothesis. 
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1.3.2.4 Effects of elevated TGF-2 in aqueous humour 
TGF-2, which is elevated in aqueous humour samples from POAG patients (117, 173-
176), is hypothesized to play a causative role in TM dysfunction (84, 177). Cultured 
TM cells treated with TGF-2 increase their ECM synthesis, which is mediated through 
connective tissue growth factor (CTGF) (178). TGF-2 also stimulates the expression 
of tissue transglutaminase (TGM2) and lysyl oxidases, which crosslink components of 
the ECM, thereby making them more resistant to degradation (179-181). TGF-2 has 
been shown to further inhibit ECM proteolysis by reducing MMP activity (182) and 
perfusion of anterior segments with TGF-2 led to reduced outflow facility (86, 183). 
These findings suggest that TGF-2 is a key player in the ECM changes observed in the 
glaucomatous TM (129, 184).  
 
The actin cytoskeleton of TM cells is also influenced by TGF-2. Mediated through 
CTGF signalling (185), TGF-2 causes elevated expression of -smooth muscle actin 
(SMA) and fibronectin, increased contractility of the actin cytoskeleton, and 
induction of actin stress fibres (185-187). Whilst it is unclear if elevated levels of TGF-
2 cause increased contractility and SMA levels in situ, differences in the actin 
cytoskeleton of TM cells have been reported between POAG and control eyes (188). 
An increased number of CLANs have been observed in glaucomatous compared to 
healthy TM cells in vitro (189), a phenomenon that is inducible by TGF-2 (190). 
However, CLANs appear to be mainly associated with steroid-induced glaucoma (191, 
192). It is worth noting that the effects of TGF-2 on TM cells are dependent on 
substrate stiffness (187), which is not reflected in in vitro studies where cells are 
grown as a monolayer on plastic ware. 
Literature review 
 
 
27 
 
1.3.2.5 Increased trabecular meshwork stiffness 
TM tissue stiffness is increased in POAG eyes when compared to normal eyes (193). 
Increased stiffness is thought to be due to the reduction in TM cells (193-195), as well 
as altered ECM deposition, increased actin cytoskeleton, and enhanced ECM 
crosslinking (147, 181). The presence of pathological calcification in the 
glaucomatous TM has also been suggested, based on the observation that enzymatic 
activity of the calcification marker alkaline phosphatase is increased and levels of 
calcification inhibitor MGP are reduced in POAG (196), thus presenting another 
potential contributor to increased TM stiffness. In cell culture experiments, increased 
substratum stiffness was linked to an increase in actin stress fibres and altered 
expression levels of several proteins including myocilin, -SMA, and TGM2 (197, 
198). These data have led some researchers to hypothesise that the increase in 
stiffness may impair the ability of TM cells to sense IOP elevation, thus preventing the 
necessary outflow modulation required to bring IOP back to a physiological level (69, 
129). 
 
1.3.2.6 Further potentially relevant mechanisms 
Many more mechanisms have been suggested to be causative of TM dysfunction, such 
as increased oxidative stress (125, 199), autophagy (200, 201), and inflammation 
(104, 108, 109). The many hypotheses that exist are not mutually exclusive and some 
attempts have been made to decipher how they relate to each other (see Figure 1.6) 
(202). Given the complex nature of POAG, it is unclear which of the observed changes 
in the TM and the aqueous humour are causal and which are a consequence of the 
disease. IOP dysregulation is yet to be fully understood and it is currently unclear how 
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these mechanisms fit together, or indeed which are the most critical to POAG 
pathogenesis. 
 
 
Figure 1.6 Model illustrating the wide range of factors thought to be involved in TM 
dysfunction, leading to increased outflow resistance and elevated IOP. Figure 
reproduced from (202). ONH: optic nerve head; IOP: intraocular pressure; TM: 
trabecular meshwork; ECM: extracellular matrix; AH: aqueous humour; ER: 
endoplasmic reticulum. 
 
1.4 SPECIFIC AIMS AND SIGNIFICANCE 
1.4.1 Thesis objective and specific aims 
The review of the literature has highlighted several gaps in our current knowledge 
regarding the changes in aqueous humour composition and how these relate to TM 
dysfunction and POAG. The objective of this thesis is to address some of these gaps, 
first by assessing changes in aqueous humour composition and relating these to 
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disease descriptors, and secondly by applying this knowledge to an in vitro cell 
culture model to assess the effect of altered aqueous humour composition on TM cell 
function. In addition to enhancing our understanding of TM cell function, such in vitro 
functional studies may also help to explain the associations determined between 
specific aqueous humour proteins and clinical measures and may ultimately identify 
new treatments for POAG. Specifically, the aims of this thesis are as follows: 
 
1) To quantify differences in aqueous humour composition between clinical 
samples from POAG and cataract control patients using multiplex assays and 
subsequently evaluate correlations with clinical parameters of POAG. 
2) To characterise a commercial human TM cell line for use as a cell culture 
model, using gene expression and functional assays. 
3) To determine the effect of a selected protein of interest (chosen from aim 1) 
on commercial human TM cells using a functional assay. 
 
1.4.2 Significance 
The mechanisms underlying TM dysfunction and IOP dysregulation remain unclear. 
In order to elucidate the disease aetiology (or potentially aetiologies), more 
information is required regarding the changes that occur in the aqueous humour and 
TM among other things. This thesis presents new insights with regards to aqueous 
humour composition, which may help to further our understanding of TM dysfunction 
and how different processes interact with each other. Furthermore, the information 
may prove to be useful in the search for biomarkers and the development of new 
diagnostic and treatment strategies. The in vitro study presented in chapter 4 forms 
a first step in the process of assessing the potential impact of specific aqueous humour 
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proteins on TM function, in an attempt to understand how the TM responds to altered 
aqueous humour composition.   
 
1.5 THESIS OUTLINE 
Chapter 1 provides an overview of the literature and highlights areas where more 
research is needed. 
 
Chapters 2 and 3 comprise two published studies, assessing a range of protein 
concentrations in aqueous humour samples from POAG and cataract control patients 
and investigating correlations with clinical descriptors including CDR, IOP, PSD, age, 
and disease duration (aim 1). 
 
Chapter 2 is concerned with MMPs and TIMPs and assesses changes in aqueous 
humour concentrations as well as altered ratios between MMPs and TIMPs, which 
interact at a 1:1 ratio.  
 
Chapter 3 investigates a series of proteins that have previously been identified in 
aqueous humour by means of discovery-based proteomic studies. This study 
highlighted HGF, FLRG and uteroglobin as proteins of interest in POAG.  
 
Chapter 4 presents the final study of this thesis and consists of the characterisation of 
commercial primary TM cells as an in vitro model, followed by an assessment of 
recombinant uteroglobin treatment on TM cell function (aims 2 and 3).  
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Finally, a general discussion, conclusions, and future directions are presented in 
Chapter 5. 
  
Chapter 2 
 TIMP1, TIMP2, AND TIMP4 ARE INCREASED IN AQUEOUS 
HUMOR FROM PRIMARY OPEN ANGLE GLAUCOMA 
PATIENTS 
 
The research contained within this chapter is unedited and has been published as: 
Ashworth Briggs EL, Toh TY, Eri R, Hewitt AW, and Cook AL. TIMP1, TIMP2, and 
TIMP4 are increased in aqueous humor from primary open angle glaucoma patients. 
Mol Vis 2015;21:1162-1172.  
 
2.1 ABSTRACT 
2.1.1 Purpose 
Elevated intraocular pressure (IOP) is the only known modifiable risk factor for 
primary open-angle glaucoma (POAG), and it can be caused by reduced aqueous 
humour outflow from the anterior chamber. Outflow is predominantly regulated by 
the trabecular meshwork, consisting of specialised cells within a complex 
extracellular matrix (ECM). An imbalance between ECM-degrading matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) within the 
trabecular meshwork is thought to contribute to POAG. This study aimed to quantify 
levels of TIMPs and MMPs in aqueous humour samples from glaucomatous and non-
glaucomatous eyes, analyse MMP/TIMP ratios, and correlate results with age, IOP and 
Humphrey’s visual field pattern standard deviation (PSD). 
 
2.1.2 Methods 
Aqueous humour samples were collected from 26 non-glaucomatous control subjects 
prior to cataract surgery and 23 POAG patients undergoing trabeculectomy or 
cataract surgery. Analyte concentrations were measured using multiplexed 
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immunoassays. Statistical significance was tested with Mann-Whitney U tests, and 
Spearman’s method was used to assess correlations with age, IOP and PSD .  
 
2.1.3 Results 
Concentrations of TIMP1 (p=0.0008), TIMP2 (p=0.002), TIMP4 (p=0.002) and 
MMP2 (p=0.020) were significantly increased in aqueous humour from POAG versus 
cataract samples. For the majority of MMP/TIMP molar ratios calculated for the 
cataract group, TIMPs outweighed MMPs. In POAG, molar ratios of MMP2/TIMP1 
(p=0.007) and MMP9/TIMP1 (p=0.005) showed a significant decrease, 
corresponding to an elevated excess of TIMPs over MMPs in POAG compared to 
cataract samples. Conversely, MMP2/TIMP3 (p=0.045) and MMP3/TIMP3 
(p=0.032) molar ratios increased. Several MMP/TIMP molar ratios correlated with 
IOP (r=0.476-0.609, p=0.007-0.034) and PSD (r= -0.482 to -0.655, p=0.005-0.046) 
in POAG samples and with age in cataract control samples.  
 
2.1.4 Conclusions 
An imbalance among MMPs and TIMPs was found in glaucomatous aqueous humour 
samples, with a shift towards raised TIMP levels. This may result in the inhibition of 
MMP activity, leading to an altered ECM composition in the TM and thereby 
contributing to increased outflow resistance. 
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2.2 INTRODUCTION 
Glaucoma is a complex optic neuropathy involving loss of peripheral vision and 
ultimately leading to blindness if untreated (4). Worldwide, over 60 million people 
are affected by glaucoma, the majority of which can be classified as having primary 
open-angle glaucoma (POAG) (13, 203). Although the disease aetiology is not 
completely understood, an elevated intraocular pressure (IOP) is a major risk factor 
and is currently the sole target of drug intervention (36, 42).  
 
Intraocular pressure is predominantly determined by the balance between aqueous 
humour production by the ciliary body and its outflow through the trabecular 
meshwork (TM) and uveoscleral pathways. The TM is a complex tissue located in the 
iridocorneal angle and consists of specialised cells embedded in an extracellular 
matrix (ECM) (68, 120, 204). Regulation of aqueous humour outflow resistance is one 
of the TM’s key roles, which is achieved by modification of the ECM composition 
(130), along with contraction of the ciliary muscle and alteration of TM cell shape to 
modify the geometry and thus permeability of the TM (118, 133). TM composition is 
known to change with age, including a reduction in TM cellularity and an increase in 
ECM accumulation (205). These alterations appear to occur largely in patients with 
glaucoma and they are considered to result in a reduced outflow facility and 
consequently increased IOP (205).  
 
ECM composition is regulated by the continual specific degradation of ECM 
components and the selective deposition of new ECM material produced by TM cells 
including collagens, glycosaminoglycans, proteoglycans, fibronectin and elastin-
containing microfibrils (68, 206, 207). Interestingly, fibronectin is also present in the 
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aqueous humour, and significantly elevated concentrations have been reported in the 
aqueous humour of POAG patients compared to cataract controls (113). The selective 
degradation of ECM components involves matrix metalloproteinases (MMPs), a 
family of secreted zinc-dependent proteinases with selective substrate specificity 
(208). MMP synthesis and activity are tightly regulated, with MMPs secreted as pro-
enzymes and activated extracellularly, where their activity is controlled by 
endogenous inhibitors (89). Tissue inhibitors of metalloproteinases (TIMPs) are 
potent albeit non-selective inhibitors of active MMPs, inhibiting proteolytic activity 
by obstructing the active site in a tight, reversible interaction with a 1:1 stoichiometry 
(90).  
 
It has been suggested that an imbalance in MMP-to-TIMP ratio could be involved in 
the development of glaucoma, due to reported changes in ECM composition and an 
increased deposition of ECM components in the TM of glaucoma patients (97). Several 
groups have also described altered MMP and TIMP concentrations in glaucomatous 
aqueous humour samples in comparison to non-glaucomatous cataract aqueous 
samples (92, 94, 97). However, the extent to which these imbalances correlate with 
any relevant clinical descriptors is not known. Thus, the aim of this study was to 
assess differences in TIMP and MMP concentrations in aqueous humour samples from 
POAG and non-glaucomatous cataract patients to evaluate changes in MMP-to-TIMP 
ratios by means of stoichiometric analyses. In addition, the study aimed to correlate 
these results with disease-associated parameters including age, IOP, optic cup-to-disc 
ratio (CDR), degree of visual field loss, quantified by Humphrey’s visual field pattern 
standard deviation (PSD) score, and disease duration. 
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2.3 MATERIALS & METHODS 
2.3.1 Patient eligibility and recruitment 
This study was approved by the Health and Medical Human Research Ethics 
Committee Tasmania (EC00337) and executed in adherence to the tenets of the 
Declaration of Helsinki. All participants were recruited through the Launceston Eye 
Doctors and the Launceston Eye Institute and gave written consent with regards to 
the donation and use of aqueous humour samples. 
 
2.3.2 Clinical assessment 
Clinical descriptors including age, IOP, CDR, PSD, and disease duration were recorded 
for POAG patients. A diagnosis of POAG was made based on the characteristic optic 
disc cupping, corresponding visual field loss and thinning of the retinal nerve fibre 
layer recorded on the ocular coherence tomography (OCT), irrespective of the 
presenting IOP. A gonioscopic examination was also performed to classify the 
anatomy of the drainage angle. IOP was measured in all patients using a calibrated 
Goldmann Applanation tonometer. For this study, only the latest treated IOP 
measurement taken during the consultation prior to the surgery was used. Vertical 
CDR was estimated by one observer (TYT) using a 60D lens during indirect slit lamp 
fundoscopy and then confirmed with an optic disc profile scan on OCT. PSD was 
obtained from the SITA Fast 24-2 Humphrey Visual Field analyser, which was used 
under standard settings. PSD was chosen over mean deviation, as the latter did not 
permit a clear differentiation between any cataract effects on the field test and 
glaucoma-induced visual field loss, specifically in glaucoma patients undergoing 
cataract surgery or a combined procedure. The PSD score emphasises a focal variation 
in the visual field that highlights typical glaucomatous field loss. A greater PSD score 
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indicates a denser field defect that correlates with disease severity. Disease duration 
was recorded as number of years since diagnosis at the time the aqueous humour 
samples were collected. All POAG patients recruited were receiving IOP-lowering 
medication, in the form of monotherapy or a combination of up to four of the following 
compounds: Timolol (-blocker), Brimatoprost, Tafluprost, Latanoprost 
(prostaglandin derivatives), Brimonidine (2 agonist), Dorzolamide and 
Brinzolamide (carbonic anhydrase inhibitors). 
 
2.3.3 Aqueous humour collection 
Aqueous humour samples (generally 50 – 100 μl) were obtained from 23 patients 
with POAG during either trabeculectomy or cataract surgery. POAG patients who had 
previously had a trabeculectomy or vitrectomy were excluded. To serve as a control, 
aqueous humour samples from 26 non-glaucomatous patients undergoing routine 
cataract surgery were collected. Case and control subjects were excluded if they had 
other retinal (such as diabetic retinopathy or age-related macular degeneration) or 
neurologic diseases. For all samples, aqueous humour was collected from the centre 
of the anterior chamber by paracentesis at the beginning of surgery, immediately 
frozen at -20°C, and transferred to -80°C within 48 hours, where they were stored for 
analysis. 
 
2.3.4 Quantification of MMPs and TIMPs 
Aqueous humour samples were analysed using the following magnetic bead-based 
multiplex assays: Magnetic Luminex Human TIMP multiplex kit (R&D Systems, Inc., 
Minneapolis, MN) and a custom Magnetic Luminex human premixed multi-analyte kit 
(R&D Systems). Using these kits, the concentrations of the following analytes were 
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measured: TIMP1 (tissue inhibitor of metalloproteinase 1), TIMP2, TIMP3, TIMP4, 
MMP-1 (matrix metalloproteinase-1), MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-
12 and MMP-13. The assays were performed in accordance with the manufacturers’ 
instructions on a Bio-Plex 200 System (Bio-Rad Laboratories, Inc., Hercules, CA). 
Aqueous humour samples were diluted 1:2.4 for the custom kit and 1:6 for the TIMP 
kit using the assay diluents provided, and 50 μl of diluted sample was added to each 
well. Fluorescence intensity (FI) was acquired and analysed using Bio-Plex Manager 
6.0. Concentrations out of range were generally below the measurable concentration, 
with the exception of TIMP1 and TIMP2 (n=3 and 1 samples, respectively), which 
gave FI readings above the highest standard and thus were excluded from all analyses. 
The number of samples in range is given for each analyte concentration reported and 
median values were determined using only the measurable samples. 
 
2.3.5 Statistical analyses 
All statistical analyses were conducted with Prism 6 (GraphPad Software, San Diego, 
CA) using two-tailed tests with a p-value <0.05 regarded as statistically significant, 
unless otherwise noted. Differences with regards to age and gender were assessed 
using an unpaired t  test and Fisher’s exact test, respectively. The D’Agostino-Pearson 
omnibus normality test was used to assess normality of analyte concentration 
distributions, and subsequent comparison of analyte concentrations between POAG 
and cataract control samples was performed using the Mann-Whitney U test. 
Correction for multiple testing was performed using Bonferroni’s method (adjusted 
p=0.004). 
 
MMPs and TIMPs in aqueous humour 
 
 
39 
 
Further analyses included a calculation of molar MMP/TIMP ratios to assess potential 
imbalances, followed by correlation of analyte concentrations and MMP/TIMP ratios 
to clinical descriptors using Spearman’s method. These analyses were performed only 
on analytes that were detected in at least 50% of cataract control and POAG samples.  
 
Due to significant differences in size between MMPs (27.9 – 76.4 kDa) and TIMPs 
(20.7 – 22.4 kDa), molecular weight was taken into consideration for stoichiometric 
analysis of MMP-to-TIMP ratios. Thus, measured protein concentrations (pg/ml) 
were converted to mol/l using the amino acid sequence obtained from the UniProtKB 
database (www.uniprot.org; access date 18 June 2014) (209). The signal sequence, 
indicated in the database, was removed prior to molecular weight calculation 
(Appendix 1) using the ExPASy ProtParam tool (web.expasy.org/protparam; access 
date 18 June 2014) (210). Stoichiometric analyses combining each MMP with each 
TIMP were performed on individual samples and reported as median values with 
interquartile range. Because TIMPs are known to be non-selective in their MMP-
inhibitory activity, we calculated all possible molar ratios using only the TIMPs and 
MMPs that were measured in more than 50% of cataract and POAG samples, with the 
number of molar ratio analyses precluding the adjustment of resulting p-values for 
multiple comparisons. Statistical significance was assessed using the Mann-Whitney 
U test (p<0.05 considered significant).  
 
2.4 RESULTS 
In this study, a total of 23 POAG and 26 cataract control samples were analysed, 
measuring all four known TIMPs and several members of the MMP family. Clinical 
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descriptors including age, IOP, PSD, CDR, and disease duration were collected for all 
POAG samples and are presented in Table 2.1. No significant differences were found 
between the cataract control and the POAG group with regards to age (p=0.226) or 
gender (p=0.245). However, a positive correlation was determined between PSD and 
CDR for the POAG group (r=0.654, p=0.0007). Correlations between all other clinical 
descriptors were non-significant. All POAG patients were treated with IOP-lowering 
medication; 95% were prescribed a prostaglandin derivative, of which 80% 
simultaneously received the -blocker Timolol. Furthermore, 43% of POAG patients 
were treated with an -2 agonist and 62% received a carbonic anhydrase inhibitor. 
The majority of POAG patients were treated with a combination of two or three 
compounds.  
 
Table 2.1 Clinical data of non-glaucomatous cataract and POAG patients 
Parameters Cataract POAG  p-value 
Age (Mean ± SD) 74.8±7.0 72.2±7.8 0.226 
Sample number (M/F) 26 (13/13) 23 (16/7) 0.245 
IOP (Median, IQR) N/A 22.0, 19.0-23.0 N/A 
PSD (Median, IQR) N/A 3.47, 2.16-8.36 N/A 
CDR (Median, IQR) N/A 0.85, 0.7-0.9 N/A 
DD (Mean ± SD) N/A 5.78±3.0  N/A 
POAG: Primary open-angle glaucoma; SD: standard deviation; M: 
male; F: female; IOP: intraocular pressure in mmHg; PSD: pattern 
standard deviation; CDR: optic cup/disc ratio; DD: disease 
duration (years); IQR: interquartile range; N/A: not available. 
Statistical significance was assessed using unpaired t test (age) 
and Fischer’s exact test (gender) and p<0.05 was considered 
significant. All POAG patients were receiving IOP-lowering 
medications and all IOPs reported correspond to treated IOPs. 
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2.4.1 The levels of TIMP1, TIMP2 and TIMP4 are significantly increased in 
glaucomatous aqueous humour samples 
In both POAG and cataract control aqueous humour samples, TIMP1, TIMP2, TIMP3 
and MMP2 were present at the highest concentrations, ranging from 4 to 25 ng/ml 
(Table 2.2). Concentrations measured for MMP3, MMP7, MMP8, MMP9 and MMP13 
were between 100 and 660 pg/ml, whereas TIMP4, MMP1 and MMP12 were present 
at concentrations below 100 pg/ml. The analyte concentrations obtained in this study 
are broadly consistent with those reported in the existing literature (92, 94, 95, 97, 
100). MMP7, MMP8, MMP12 and MMP13 could only be measured in a small number 
of samples (Table 2.2), with ≥50% of samples below the detection limits of the assay 
in both POAG and cataract control samples; consequently, these analytes were 
excluded from all subsequent analyses. Nevertheless, the proportion of samples in 
which MMP7, MMP8, MMP12 and MMP13 were out of range was not significantly 
different between the control and POAG groups (Fisher’s exact test p=0.184 – 1.0).  
 
A comparison of POAG aqueous humour samples to cataract control samples revealed 
higher concentrations in POAG for the majority of analytes, but for many this 
difference did not reach statistical significance. However, significant differences in 
concentration were seen for TIMP1 (p=0.0008), TIMP2 (p=0.002) and TIMP4 
(p=0.002), with all three analytes presenting an increased median concentration in 
POAG (Table 2.2 and Figure 2.1). The increases in TIMP1, TIMP2 and TIMP4 remained 
significant after correction for multiple testing (adjusted p-value = 0.004). In 
addition, the median concentration of MMP2 was also increased in POAG (p=0.020; 
Table 2.2 and Figure 2.1). No sample was consistently above the 95th percentile across 
all analytes measured, and with regards to the statistically significant analytes, the 
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highest concentrations plotted in Figure 2.1 stem from different individuals. 
Furthermore, the highest concentrations measured for TIMP1 and TIMP2 were 
outside the range of the assay standard curve and thus for TIMP1 and TIMP2, these 
samples were excluded prior to analysis. 
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Table 2.2 Aqueous humour analyte concentrations in cataract control versus POAG 
 
 
 
 
 
 
 
 
 
 Cataract  POAG  
Analyte Median IQR In Range  Median IQR In Range p-value 
TIMP1 7235 6062-8508 24/24  11226 8757-18434 17/20 0.0008 
TIMP2 15298 13200-17767 24/24  20735 16167-30406 19/20 0.002 
TIMP3 3967 2941-5380 24/24  4610 2941-6647 20/20 0.396 
TIMP4 43.9 43.9-50.3 15/24  57.6 47.2-97.6 16/20 0.002 
MMP1 25.0 18.5-34.4 25/26  31.5 16.9-99.0 22/23 0.406 
MMP2 20641 16730-24127 26/26  24965 20458-36854 22/23 0.020 
MMP3 418.3 293.4-644.5 25/26  660.3 318.8-1272.0 23/23 0.149 
MMP7 261.8 230.2-270.5 3/26  361 178-637 8/23 0.606 
MMP8 208.8 53.9-293.2 7/26  108.4 57.8-181.8 6/23 0.311 
MMP9 187.6 129.4-347.4 26/26  179.6 114.6-376.5 22/23 0.778 
MMP12 36.2 28.9-39.7 6/26  38.3 33.6-45.9 5/23 0.307 
MMP13 140.9 107.8-206.0 10/26  199.2 155.2-205.8 6/23 0.367 
Median and interquartile range (IQR) calculated for values in range reported as pg/ml. Significance 
was tested using the Mann-Whitney U test and a p-value <0.05 was considered significant. 
Correction for multiple testing was performed using Bonferroni’s method (adjusted p-value= 
0.004) and p-values that remained significant are highlighted in bold. 
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Figure 2.1 Distribution of TIMP1 (A), TIMP2 (B), TIMP4 (C) and MMP2 (D) 
concentrations in aqueous humor from non-glaucomatous cataract (blue) versus POAG 
(orange). Levels of all four analytes shown were significantly increased in POAG 
aqueous humor, as determined using Mann-Whitney U (p<0.05). Medians and 
interquartile ranges are indicated. See Table 2.2 for complete list of analyte 
concentrations measured. 
 
Due to the known role of TIMPs as MMP inhibitors, we sought to determine the 
presence of an imbalance between specific MMP and TIMP proteins. Thus, MMP/TIMP 
stoichiometric ratios were calculated (Table 2.3 and Figure 2.2). With the exception 
of MMP2/TIMP3, MMP2/TIMP4, MMP3/TIMP4 and MMP9/TIMP4, the molar 
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concentration of TIMP was higher than that of each MMP for all other median ratios 
presented in Table 2.3. When comparing the POAG group to cataract controls, the 
molar ratios of MMP2/TIMP1 (p=0.007) and MMP9/TIMP1 (p=0.005) showed a 
significant decrease in POAG samples, corresponding to an elevated excess of TIMPs 
over MMPs in POAG versus cataract samples. Conversely, the MMP2/TIMP3 
(p=0.045) and MMP3/TIMP3 (p=0.032) molar ratios increased. These significant 
changes to MMP/TIMP molar ratios are likely due to the increase in TIMP1, TIMP2, 
and TIMP4 concentrations in POAG, as little difference was observed in MMP levels. 
Furthermore, the molar ratios demonstrate that in terms of total TIMP concentration, 
the increases in TIMP1, 2 and 4 outweigh the rise in total MMP2 concentration 
observed. 
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Table 2.3 Stoichiometric analysis of MMP and TIMP ratios in cataract control versus POAG samples 
 
 
 
 Cataract  POAG  
Ratio Median Interquartile range N  Median Interquartile range N p-value 
MMP1/TIMP1 1.28 x10-3 8.68 x10-4-2.07 x10-3 23  1.20 x10-3 6.17 x10-4-1.96 x10-3 16 0.353 
MMP1/TIMP2 6.25 x10-4 4.65 x10-4-1.09 x10-3 23  5.88 x10-4 3.78 x10-4-1.22 x10-3 18 0.857 
MMP1/TIMP3 2.46 x10-3 1.57 x10-3-3.40 x10-3 23  2.69 x10-3 1.58 x10-3-1.47 x10-2 19 0.193 
MMP1/TIMP4 0.24 0.18-0.34 15  0.33 0.22-0.65 16 0.108 
MMP2/TIMP1 0.74 0.69-1.04 24  0.64 0.46-0.77 16 0.007 
MMP2/TIMP2 0.40 0.33-0.46 24  0.35 0.30-0.41 18 0.137 
MMP2/TIMP3 1.32 1.06-1.88 24  2.01 1.48-2.29 19 0.045 
MMP2/TIMP4 155.10 133.20-170.50 15  144.10 126.80-167.00 16 0.245 
MMP3/TIMP1 2.40 x10-2 1.66 x10-2-3.97 x10-2 23  2.52 x10-2 1.27 x10-2-2.91 x10-2 17 0.492 
MMP3/TIMP2 1.09 x10-2 9.16 x10-3-2.31 x10-2 23  1.53 x10-2 9.50 x10-3-2.56 x10-2 19 0.528 
MMP3/TIMP3 4.26 x10-2 3.04 x10-2-8.22x10-2 23  7.10 x10-2 4.29 x10-2-2.24 x10-1 20 0.032 
MMP3/TIMP4 4.68 3.70-7.60 15  7.26 4.04-13.65 16 0.354 
MMP9/TIMP1 8.55 x10-3 4.91 x10-3-1.25 x10-2 24  4.64 x10-3 2.20 x10-3-9.11 x10-3 16 0.005 
MMP9/TIMP2 4.10 x10-3 2.46 x10-3-6.55 x10-3 24  2.70 x10-3 1.74 x10-3-4.70 x10-3 18 0.124 
MMP9/TIMP3 1.45 x10-2 8.05 x10-3-2.88 x10-2 24  1.42 x10-2 7.96 x10-3-2.74 x10-2 19 0.631 
MMP9/TIMP4 1.47 0.69-2.55 15  1.17 0.60-1.99 16 0.397 
Values represent median stoichiometric ratio with interquartile range. Significance was tested by means of 
Mann-Whitney U and a p-value <0.05 was considered significant, as highlighted in bold. N: number of ratios 
calculated. 
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Figure 2.2 Distribution of MMP/TIMP ratios in cataract versus POAG patients. 
Stoichiometric ratios were calculated for individual aqueous humour samples from 
non-glaucomatous cataract (blue; N=23-24) and POAG (orange; N=16-20) patients. 
Median ratios and interquartile ranges are indicated. The ratios for MMP2/TIMP1 (A), 
MMP2/TIMP3 (B), MMP3/TIMP3 (C) and MMP9/TIMP1 (D) were significantly 
different between cataract and glaucoma (p<0.05), as determined using Mann-
Whitney U. See Table 2.3 for full set of ratios calculated. 
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2.4.2 Several MMP/TIMP molar ratios correlate with IOP and PSD in glaucomatous 
aqueous humour samples 
Spearman’s rank correlation method was used to assess the correlation of each 
analyte concentration and MMP/TIMP ratio with age for both POAG and cataract 
samples (Table 2.4). Significant positive correlations were determined between age 
and TIMP1 (r=0.492, p=0.015), TIMP3 (r=0.413, p=0.045) and MMP3 (r=0.537, 
p=0.006). Furthermore, MMP3/TIMP1 (r=0.529, p=0.010) and MMP3/TIMP2 
(r=0.492, p=0.017) also presented positive correlations with age in cataract samples. 
Nevertheless, none of these analytes or molar ratios correlated with age for POAG 
samples. 
 
Table 2.4 Correlation of measured analytes and MMP/TIMP ratios to age for cataract 
control and POAG samples 
 
 
 
 
 
 
 
 
 
 
Correlations with IOP, PSD, disease duration (Table 2.5) and CDR (Appendix 2) were 
determined for analyte concentrations and MMP/TIMP ratios for POAG samples. 
 Cataract  POAG 
Analyte/ratio rs p-value N  rs p-value N 
TIMP1 0.492 0.015 24  -0.012 0.949 17 
TIMP3 0.413 0.045 24  0.011 0.962 20 
MMP1 0.388 0.055 25  0.115 0.612 22 
MMP3 0.537 0.006 25  0.052 0.814 23 
MMP2/TIMP4 -0.104 0.686 15  0.443 0.087 16 
MMP3/TIMP1 0.529 0.010 23  0.346 0.173 17 
MMP3/TIMP2 0.492 0.017 23  -0.045 0.855 19 
MMP9/TIMP4 0.509 0.055 17  0.074 0.785 16 
Correlation of analyte concentrations and MMP/TIMP ratios to age 
were determined using Spearman’s rank correlation method. A p-
value <0.05 was considered significant, as shown in bold. Only 
correlations with p<0.1 and their corresponding values for the 
other group are shown.  rs: Spearman correlation coefficient; N: 
number of correlation pairs. 
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Molar ratios for MMP1 in combination with any of the four TIMPs, as well as 
MMP3/TIMP3 and MMP9/TIMP3, correlated positively with IOP (p=0.007-0.034; 
Table 2.5). Several molar ratios also correlated negatively with PSD (p=0.005-0.046), 
and MMP9/TIMP1 correlated positively with disease duration (p=0.015), whereas no 
significant correlations were determined for CDR. 
 
Table 2.5 Correlation of measured analytes and MMP/TIMP ratios to PSD, IOP and 
disease duration for POAG samples 
 
 
2.5 DISCUSSION 
An imbalance between MMPs and TIMPs in aqueous humour has been suggested to 
play a role in the development of glaucoma (97). In this study, we quantified aqueous 
humour concentrations of TIMP 1-4 and several MMPs in POAG and cataract samples, 
 IOP  PSD  disease duration  
Analyte/ratio rs p-value  rs p-value  rs p-value N 
MMP1 0.402 0.063  -0.147 0.516  0.134 0.553 22 
MMP1/TIMP1 0.594 0.017  -0.538 0.034  0.368 0.161 16 
MMP1/TIMP2 0.609 0.007  -0.482 0.043  0.240 0.338 18 
MMP1/TIMP3 0.491 0.033  -0.407 0.084  0.215 0.378 19 
MMP1/TIMP4 0.550 0.029  -0.556 0.028  0.005 0.976 16 
MMP3/TIMP1 0.423 0.091  -0.655 0.005  0.316 0.216 17 
MMP3/TIMP2 0.431 0.065  -0.492 0.032  0.050 0.838 19 
MMP3/TIMP3 0.476 0.034  -0.348 0.133  0.166 0.484 20 
MMP3/TIMP4 0.393 0.132  -0.509 0.046  -0.165 0.505 16 
MMP9/TIMP1 0.247 0.353  -0.300 0.258  0.605 0.015 16 
MMP9/TIMP2 0.334 0.175  -0.313 0.207  0.460 0.055 16 
MMP9/TIMP3 0.527 0.020  -0.454 0.051  0.283 0.241 19 
MMP9/TIMP4 0.467 0.070  -0.409 0.117  0.378 0.149 16 
Correlation of analytes and MMP/TIMP ratios to IOP (intraocular pressure), PSD 
(Humphrey’s visual field pattern standard deviation), and disease duration were 
determined using Spearman’s rank correlation. A p-value of <0.05 was considered 
significant, as shown in bold. Only correlations with p<0.1 and their corresponding 
values for the other clinical descriptors are shown. rs: Spearman correlation 
coefficient; N: number of correlation pairs (applies to all analyses). 
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assessed changes in MMP/TIMP molar ratios, and correlated these results with 
clinical descriptors. A significant increase in the concentrations of TIMP1, TIMP2 and 
TIMP4 was determined in POAG compared to cataract samples, which is broadly 
consistent with several reports in the literature (92, 94, 95, 97, 100). Unlike most 
other studies of MMP and TIMP levels in aqueous humour, we have included clinical 
data in our analyses and found that several of the MMP/TIMP molar ratios calculated 
for POAG aqueous humour samples correlated strongly with IOP, PSD or both.  
 
Our results reveal an overall dominance of TIMPs over MMPs in cataract aqueous 
humour samples. However, the increased concentrations of TIMP1, TIMP2 and TIMP4 
produce an MMP/TIMP molar ratio that is imbalanced in the aqueous humour of 
POAG patients compared to that of cataract patients and suggests that overall MMP 
activity may be decreased in POAG. All TIMPs are said to be able to inhibit all MMPs, 
with only a few exceptions. However, TIMP3 is more effective at inhibiting other 
enzymes such as ADAMs and ADAMTs compared to MMPs (208). Thus, in this study, 
all TIMPs relevant to MMP inhibition are upregulated in POAG aqueous humour, 
consistent with the reduction in active MMP levels reported for glaucomatous 
aqueous humour samples (97). This observation may contribute to a reduced 
clearance of ECM components and is in agreement with the reported increase in ECM 
deposition within the glaucomatous TM (205).  
 
Several significant correlations with age were found for TIMPs, MMPs and MMP/TIMP 
molar ratios in cataract samples, which may contribute to the known age-associated 
increase in ECM deposition within the TM of healthy individuals (205). In contrast, no 
such associations with age were observed in POAG samples, despite the larger extent 
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to which this occurs in the glaucomatous TM. However, a correlation was determined 
between the MMP9/TIMP1 molar ratio and disease duration in POAG samples.  
 
Glaucoma has been described as a disease of early and accelerated cell senescence 
(153, 211, 212), a state in which cells permanently exit the cell cycle but remain 
metabolically active. A higher number of senescent cells in the TM of POAG patients 
compared to age-matched control individuals has been reported (153, 211, 212). 
Thus, changes in gene expression associated with senescence, which include 
increased secretion of TIMPs and MMPs (213), may contribute to the increased 
aqueous humour concentration of TIMPs reported here. It is possible that senescence-
associated increases of MMP and TIMP secretion occur to varying extents in different 
POAG patients, and this may reduce the extent of correlation between these proteins 
and age. IOP may also modify the levels of MMPs and TIMPs by causing mechanical 
stretch of the TM, which alters the secretion of MMPs and TIMPs (214). This action 
has been suggested to involve TGF1 as a signalling intermediate (215). Thus, it is 
plausible that TM cells are directly involved in the change of MMP and TIMP levels in 
the aqueous humour. 
 
In POAG samples, MMP/TIMP imbalances were correlated with an elevated PSD score 
and therefore deterioration of the visual field (indicated by negative correlations 
between several MMP/TIMP molar ratios and PSD). An association between elevated 
IOP and the progression of visual field defects has been shown (216), and the 
hypothesis that decreased MMP activity within the TM leads to elevated IOP is well 
described (130). Based on these findings, one may expect that the further imbalance 
of TIMPs over MMPs in POAG samples compared to cataract samples described here 
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is likely to reduce ECM turnover, increase aqueous humour outflow resistance and 
thereby elevate IOP. However, we found that increased concentration of TIMPs 
altered the MMP/TIMP ratio such that a more pronounced imbalance correlated with 
a lower IOP. This may be due to treatment with hypotensive medication decreasing 
IOP to a variable extent between patients, or their impact on MMP and TIMP levels in 
the aqueous humour (217). Several IOP-lowering drugs have been tested in Sprague-
Dawley rats and in cell cultures (human fibroblasts and keratocytes) and have been 
shown to affect the expression of some MMPs and TIMPs (218). Broadly, the 
prostaglandin derivative Latanoprost and -2 agonist Brimonidine caused an 
increase in MMP3 and decreases in TIMP1 and TIMP3, whereas the -blocker Timolol 
had the opposite effect. However, the effects of combinatorial treatments were not 
assessed in this study; therefore, such experiments do not fully reflect current 
treatment regimens, which often involve a combination of two or more compounds. 
In this present study, most POAG patients were being treated with a prostaglandin 
analogue (95%), of which 80% simultaneously received Timolol, and notably, no 
difference in MMP3 concentration between POAG and cataract samples was observed. 
Nevertheless, it is possible that the IOP-lowering treatments used in the care of the 
POAG study participants may have affected the MMP or TIMP concentrations reported 
here. 
 
The positive correlations between MMP/TIMP ratios and IOP described in this study 
are also difficult to reconcile with current knowledge of TIMPs as potent MMP 
inhibitors. However, TIMPs have recently been shown to possess additional activities 
independent of their roles as MMP inhibitors, including regulation of cell growth, 
differentiation, migration, and apoptosis, mediated through direct interactions 
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between TIMPs and cell surface receptors (219, 220). Increased TIMP expression in 
glaucomatous aqueous humour may therefore have as yet unrecognised MMP-
independent effects, such as a direct inhibition of other TM cell functions, including 
contractibility and phagocytosis, which may affect aqueous humour outflow (118, 
133), or contributing to the observed loss of cellularity within the TM of glaucomatous 
eyes, which may involve apoptotic signalling mechanisms (77, 152, 221, 222). 
Although the effect of TIMPs on apoptosis appears to be highly context-dependent 
(223), with several studies reporting pro- and anti-apoptotic responses to TIMP 
signalling (219), the positive correlations between MMP/TIMP ratios and IOP suggest 
that a higher IOP may be associated with a loss of anti-apoptotic (or pro-survival) 
TIMP signalling. This may lead to decreased cellularity within the TM and 
consequently insufficient drainage of aqueous humour.  
 
The strong correlations determined between MMP/TIMP ratios and the clinical 
determinants IOP and PSD indicate that the imbalance between MMPs and TIMPs is 
likely of importance in POAG. Nevertheless, it remains unknown whether the changes 
observed in POAG aqueous humour composition are a cause or consequence of the 
disease, and whether TIMP levels increase as a response to altered MMP secretion or 
vice versa, or indeed as a response to other events occurring in the anterior chamber. 
In conclusion, this study suggests that further work should focus on TIMPs, not only 
with respect to changes in ECM composition, but also the cellularity of the TM in 
POAG.  
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 UTEROGLOBIN AND FLRG CONCENTRATIONS IN AQUEOUS 
HUMOUR ARE ASSOCIATED WITH AGE IN PRIMARY OPEN 
ANGLE GLAUCOMA PATIENTS 
 
The research contained within this chapter is unedited and has been published as: 
Ashworth Briggs EL, Toh TY, Eri R, Hewitt AW, and Cook AL. Uteroglobin and FLRG 
concentrations in aqueous humour are associated with age in primary open angle 
glaucoma patients. BMC Ophthalmology 2018;18:57-64. 
 
3.1 ABSTRACT 
3.1.1 Background 
The pathophysiological changes occurring in the trabecular meshwork in primary 
open-angle glaucoma are poorly understood, but are thought to include increased 
extracellular matrix deposition, trabecular meshwork cell apoptosis, inflammation, 
trabecular meshwork calcification and altered protein composition of the aqueous 
humour. Although many proteins are present in aqueous humour, relatively few have 
been studied extensively, and their potential roles in primary open-angle glaucoma 
are unknown. 
 
3.1.2 Methods 
Analyte concentrations in aqueous humour from 19 primary open-angle glaucoma 
and 18 cataract patients were measured using a multiplex immunoassay. Fisher’s 
exact test was used to assess statistical significance between groups, and correlations 
of analyte concentrations with age, intraocular pressure, pattern standard deviation, 
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mean deviation, cup-to-disc ratio and disease duration since commencing treatment 
were tested by Spearman’s method. 
 
3.1.3 Results 
CHI3L1, FLRG, HGF, MIF, p-selectin and uteroglobin were detected in more than 50% 
of samples of one or both patient groups, some of which have not previously been 
quantified in aqueous humour. In the glaucoma but not the cataract group, significant 
correlations were determined with age for uteroglobin/SCGB1A1 (rs=0.805, 
p<0.0001) and FLRG (rs=0.706, p=0.0007). Furthermore, HGF correlated 
significantly with disease duration (rs=-0.723, p=0.0007). There were no differences 
in analyte concentrations between groups, and no other significant associations with 
clinical descriptors that passed correction for multiple testing. 
 
3.1.4 Conclusions 
The correlations of uteroglobin and FLRG with age in primary open-angle glaucoma 
but not cataract may suggest a heightened requirement for anti-inflammatory 
(uteroglobin) or anti-calcification (FLRG) activity in the ageing glaucomatous 
trabecular meshwork. 
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3.2 INTRODUCTION 
Aqueous humour is a clear fluid that circulates throughout the anterior chamber of 
the eye to provide nutrients to and remove metabolic waste products from the tissues 
it contacts, and thus contributes to the maintenance of normal eye function (4). The 
majority of aqueous humour drains from the eye via the trabecular meshwork (TM), 
a specialised porous tissue responsible for the regulation of intraocular pressure 
(IOP) (224). In primary open-angle glaucoma (POAG), decreased drainage of aqueous 
humour through a compromised TM leads to elevated IOP (4), causing optic nerve 
degeneration and thus a progressive loss of peripheral vision unless treated. Elevated 
IOP is the only modifiable risk factor for the development of glaucoma, and all current 
treatments for POAG are aimed at reducing IOP (224). 
 
The molecular and cellular changes that contribute to TM dysfunction and elevated 
IOP in POAG are poorly understood. Several processes, including altered extracellular 
matrix (ECM) turnover (205), oxidative stress (225), inflammation (226), reduced 
TM cellularity (152), increased TM stiffness (193) and TM calcification (227) are all 
potential contributors to the pathological changes occurring in the TM during POAG. 
Many clinical studies of glaucomatous aqueous humour samples have reported 
alterations of multiple inflammatory mediators, including TGF2 (173, 174, 228), IL-
8 (103), IL12, IFNγ and CXCL9 (104, 229) compared to controls, and a pro-
inflammatory environment of the aqueous humour has been reported for an animal 
model of glaucoma (230). Furthermore, inflammation can cause TM cell apoptosis 
and lead to a dysfunctional TM, thus contributing to an elevated IOP (226). 
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Whilst many proteins have been detected in aqueous humour using discovery-based 
proteomics approaches (74, 75, 77, 231-234), detailed studies have been performed 
with regards to these proteins, and thus any potential role in eye physiology or 
diseases such as glaucoma remains undetermined. Increased knowledge of the 
proteins present in aqueous humour from POAG patients may provide clues to 
improve our understanding of the disease processes involved and how they interact 
with each other. Accordingly, the aims of this study were to compare the 
concentrations of selected proteins from these studies, including several not 
previously analysed in eye diseases, in aqueous humour samples obtained from a 
well-defined cohort of 19 POAG patients against 18 non-glaucomatous cataract 
samples. Subsequently, we sought to determine the extent of correlation between 
each of these proteins and relevant clinical descriptors including age, IOP, field of 
vision (quantified by Humphrey’s visual field pattern standard deviation (PSD) score 
and mean deviation (MD)), optic cup/disc ratio (CDR) and disease duration since 
commencing treatment. Here, we report the concentrations of six aqueous humour 
proteins, and identify significant correlations of age with uteroglobin and FLRG 
specific to the POAG group, as well as a correlation of HGF with POAG disease 
duration. 
 
3.3 MATERIALS & METHODS 
3.3.1 Patient eligibility and recruitment 
This study was approved by the Health and Medical Human Research Ethics 
Committee Tasmania (H0013264) and executed in adherence to the tenets of the 
Declaration of Helsinki. All participants were recruited through Tze’Yo Toh at the 
Launceston Eye Institute and gave written consent with regards to donation and use 
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of aqueous humour samples. POAG was diagnosed based on characteristic optic disc 
cupping, corresponding visual field loss, and retinal nerve fibre layer thinning, 
regardless of the presenting IOP. The anatomy of the drainage angle was assessed by 
gonioscopic examination. Non-glaucomatous cataract patients (referred to herein as 
the cataract group) were recruited to serve as a control for this study. POAG patients 
who had previously had a trabeculectomy or vitrectomy were excluded from this 
study. Furthermore, POAG and cataract subjects were excluded if they had other 
retinal (such as diabetic retinopathy or age-related macular degeneration) or 
neurological disease. 
 
Clinical descriptors including age, IOP and CDR were recorded for both patient 
groups. IOP was measured in all patients using a calibrated Goldmann Applanation 
tonometer. For POAG patients, only the latest treated IOP measurement taken during 
the consultation prior to the surgery was used for this study. Vertical CDR was 
estimated by one observer (Tze’Yo Toh), using a 60D lens during indirect slit lamp 
fundoscopy and further confirmed with an optic disc profile scan using optical 
coherence tomography. MD and PSD were included as measures for vision loss but 
were not available for all patients (MD was recorded for 13/19 POAG and 5/18 
cataract patients, PSD for 19/19 POAG and 6/18 cataract patients). Furthermore, 
disease duration since commencing treatment was noted for POAG patients at the 
time aqueous humour samples were collected. 
 
All POAG patients recruited were receiving IOP-lowering eye drops, in the form of 
monotherapy, or a combination of up to four of the following compounds: Timolol (-
blocker), Bimatoprost, Tafluprost, Latanoprost, Travoprost (prostaglandin 
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derivatives), Brimonidine (-2 agonist) and Brinzolamide (carbonic anhydrase 
inhibitor). 
 
3.3.2 Aqueous humour collection 
Aqueous humour samples (50–100 μl) were collected from 19 patients with POAG 
during routine cataract surgery. Aqueous humour was also collected from 18 non-
glaucomatous patients undergoing routine cataract surgery to serve as a control for 
this study (75, 235). For all samples, aqueous humour was collected from the centre 
of the anterior chamber by paracentesis at the beginning of surgery, immediately 
frozen at -20°C, and transferred to -80°C within 48 hours, where they were stored for 
analysis. 
 
3.3.3 Multiplex immunoassay 
We used discovery-based proteomic studies of aqueous humour in combination with 
other relevant scientific literature to select 30 proteins for inclusion in a custom 
magnetic bead-based multiplex immunoassay (R&D Systems, Inc., Minneapolis, MN) 
to enable simultaneous measurement of each protein in aqueous humour samples 
from. The 30 proteins included were: angiopoietin-1, angiopoietin-2, BMP2, BMP4, 
BMP9, CCL27/CTACK, CHI3L1/YKL-40, collagen IV alpha 1, cripto-1, DcR3, EGF, 
endoglin/CD105, endothelin-1, EPO, FLRG, follistatin, growth hormone, HGF, IGFBP-
1, IGFBP-3, IL-6, IL-9, LIF, MFG-E8, MIF, p-Selectin, thrombospondin-2, uteroglobin, 
VCAM-1 and vWF-A2. Some of these proteins (endothelin-1, HGF, EPO, MIF) have 
previously been shown to be present in aqueous humour using immunoassay 
techniques, but there are scant or no subsequent studies reporting correlation to 
clinical descriptors (103, 111, 112, 114, 236, 237). Others (e.g. thromobospondin-2, 
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follistatin) have been shown to be altered in animal (238) or cell culture-based (239) 
models of glaucoma, but there are no reports of their levels in aqueous humour. We 
also selected several proteins (e.g. CHI3L1, CTACK, cripto-1, DcR3, endoglin, 
uteroglobin, FLRG, MFG-E8, p-selectin) that have been identified as being present in 
aqueous humour (75), but for which there is a paucity of studies characterising their 
involvement in glaucoma. 
 
The assay was performed in accordance with manufacturers’ instructions on a Bio-
Plex 200 System (Bio-Rad Laboratories, Inc., Hercules, CA). Aqueous humour 
dilutions with assay diluent were kept to a minimum, with dilution factors ranging 
from 1.5 – 5.5, sufficient to allow loading of 50 μl of diluted sample per assay well. 
Fluorescence intensity (FI) was measured and analysed using Bio-Plex Manager 6.0. 
The majority of concentrations out of range were below the detection limit for the 
relevant analyte, with the exception of MIF, which resulted in FIs above the highest 
standard for two cataract and three POAG samples. Readings out of range of the 
standard curve were excluded from all subsequent analyses. The concentration 
ranges of the standard curves and the number of samples in range for each analyte 
tested are given in Appendix 3. 
 
3.3.4 Normalisation to total protein concentration 
Total aqueous humour protein concentration was measured using a BCA protein 
assay (Thermo Fisher Scientific, Waltham, MA). Aqueous humour samples were 
diluted 6-fold in ultrapure water and assessed as described in the manufacturer’s 
protocol. Individual analyte concentrations were normalised to total protein 
concentration for each sample prior to calculation of correlations as described below. 
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3.3.5 Statistical analyses 
All statistical analyses were conducted with Prism 6 (GraphPad Software, San Diego, 
CA), using unpaired two-tailed tests with a significance threshold of p=0.05. 
Differences in age, IOP, CDR and total protein concentration were assessed using 
unpaired T-tests, MD and PSD were evaluated with a Mann-Whitney U test due to non-
Gaussian data distribution, and gender was tested using Fisher’s exact test. Analyte 
concentrations measured for POAG and cataract samples were grouped and the 
number of samples within range versus out of range of the standard curve were 
compared using Fisher’s exact. Due to the non-normal distributions obtained for some 
analyte data sets, correlations with clinical descriptors were calculated using the non-
parametric Spearman’s method (rs: Spearman’s correlation coefficient). To minimise 
identification of false associations in our data, Bonferroni’s method was used to 
correct for multiple testing of the analyte concentration data set across different 
analyses, resulting in an adjusted significance threshold of p = 0.0017 (conventional 
threshold of 0.05/30 protein analytes = adjusted threshold of p = 0.0017). 
 
3.4 RESULTS 
In this study, aqueous humour samples from 19 POAG and 18 non-glaucomatous 
cataract patients were analysed using a multiplex assay, to quantify the 
concentrations of 30 proteins reported to be present in aqueous humour (75, 77). 
Clinical descriptors including age, IOP and CDR were collected for all patients and are 
presented in Table 3.1. MD and PSD were included as measures of vision loss; 
however, MD data was only available for 13 POAG and 5 cataract patients, and PSD 
for 6 cataract patients (Table 3.1). In addition, disease duration since commencing 
treatment was recorded for the POAG group (Table 3.1). There were no significant 
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differences between cataract and POAG groups with regards to age (p=0.335), gender 
(p=0.313), IOP (p=0.783) or total aqueous protein concentration (p=0.077). Whilst 
the differences in MD and PSD were also non-significant (p=0.846 and p=0.0818, 
respectively), this is likely due to the lack of data for the majority of cataract patients. 
The difference in CDR was statistically significant, with a mean CDR of 0.78 in POAG 
compared to 0.40 in the cataract group (p<0.0001). All patients in the POAG cohort 
were receiving IOP-lowering medication, with 63% (12/19) on a monotherapy 
regime of one prostaglandin derivative. The remaining patients received a 
combination of up to four compounds. All POAG patients were treated with a 
prostaglandin derivative, and 32% (6/19) were simultaneously prescribed with 
Timolol (β-blocker). A small percentage of patients received an α-2 agonist (1/19) 
and/or a carbonic anhydrase inhibitor (2/19) in addition to the prostaglandin 
derivative and β-blocker. In this initial study, we have not attempted to assess 
differences in analyte concentrations due to specific medication regimes. 
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Table 3.1 Clinical data for non-glaucomatous cataract and POAG patients 
Parameters Cataract POAG  p-value 
Age (years; Mean ± SD) 66.5±7.0 68.9±7.9 0.335 
Sample number (M/F) 18 (5/13) 19 (9/10) 0.313 
IOP (Mean, ± SD) 17.9±3.5 17.6±3.4 0.783 
MD (Median, IQR) -3.1, -4.8 to -0.9 -3.6, -4.8 to -2.0 0.846 
PSD (Median, IQR) 1.63, 1.40 - 2.95 2.11, 1.69 – 5.26 0.082 
CDR (Mean ± SD) 0.40, 0.22 0.78, 0.09 <0.0001 
Disease duration  
(years; Mean ± SD) 
N/A 2.59, 2.15 N/A 
AH total protein  
(mg/ml; Mean ± SD) 
3.21±0.88 3.77±0.97 0.077 
POAG: Primary open-angle glaucoma; SD: standard deviation; M: male; F: 
female; IOP: intraocular pressure in mmHg; MD: mean deviation; IQR: 
interquartile range; PSD: Humphrey’s visual field pattern standard 
deviation; CDR: optic cup/disc ratio; N/A: not applicable; AH: aqueous 
humour. Statistical significance was assessed using Fischer’s exact test 
(gender), unpaired T-test (age, IOP, CDR, total protein) and Mann-
Whitney U-test (MD, PSD) with p<0.05 considered significant. 
 
 
Out of the 30 proteins tested, 6 were detectable in 50% of samples in one or both 
groups: CHI3L1, FLRG, HGF, MIF, p-selectin and uteroglobin (Table 3.2). The 
remaining 24 analytes were either not detected, or detected in only a small number 
of samples, and were therefore excluded from all subsequent analyses (see Appendix 
3). Of those proteins analysed further, CHI3L1 was present at the highest levels, with 
median concentrations above 65 ng/ml. FLRG and MIF were detected at intermediate 
levels, with median concentrations ranging from 3.6 to 6 ng/ml, whereas HGF, p-
selectin and uteroglobin were all quantified at median concentrations below 1 ng/ml. 
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Table 3.2 Aqueous humour analyte concentrations in non-glaucomatous cataract 
versus POAG 
 Cataract  POAG  
Analyte Median IQR 
In 
Range 
 
Median IQR 
In 
Range 
p-value 
CHI3L1 65171 53191-
91124 
18/18  83122 65958-
95018 
19/19 1.000 
FLRG 3614 2857-
4412 
16/18  4303 3679-
5323 
19/19 0.230 
HGF 171.2 114-227 9/18  170.7 133-222 18/19 0.003 
MIF 5592 4061-
10039 
15/18  4809 3697-
5830 
15/19 1.000 
p-selectin 791 691-874 9/18  927 803-1193 15/19 0.091 
uteroglobin 335 198-463 17/18  253 174-477 18/19 1.000 
Median and interquartile range (IQR) calculated for data in range, reported as pg/ml. 
Significance was tested using the Fisher’s exact test for comparison of number of 
detected vs. undetected samples in each group. Following correction for multiple testing 
using Bonferroni’s method, a p-value of <0.0017 was considered significant. 
 
 
The number of samples in range versus below the range of the standard curve were 
compared for each analyte using Fisher’s exact test. Whilst analysis revealed a 
difference for HGF (p=0.003) between cataract (9/18 in range) and POAG (18/19 in 
range), the result did not pass correction for multiple testing (adjusted p-value 
threshold = 0.0017). In addition, no sample was consistently below the 5th or above 
the 95th percentile for all analytes reported. 
 
3.4.1 Significant correlation of FLRG and uteroglobin with age in POAG but not 
cataract 
Prior to calculating correlations, analyte concentrations were normalised using total 
aqueous humour protein concentration. The total protein concentrations determined 
for POAG and cataract samples (mean concentrations of 3.77 and 3.21 mg/ml, 
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respectively) did not differ significantly between groups (p=0.077). Similarly, 
normalised analyte concentrations did not differ significantly between the POAG and 
cataract group (Figure 3.1). 
 
 
Figure 3.1 Normalised analyte distributions in cataract and primary open-angle 
glaucoma (POAG) samples. Distribution of CHI3L1 (A), FLRG (B), HGF (C), MIF (D), p-
selectin (E) and uteroglobin (F) concentrations in aqueous humour normalised to total 
aqueous humour protein concentration from non-glaucomatous cataract (blue) and 
POAG (orange). Median and interquartile range are indicated. 
 
Correlations between normalised analyte concentrations and age were assessed for 
both patient groups (Table 3.3). Significant positive correlations were obtained with 
FLRG (rs=0.706, p=0.0007) and uteroglobin (rs=0.805, p<0.0001) for POAG but not 
the cataract group (rs=0.475, p=0.065 and rs=0.555, p=0.022, respectively). Whilst 
further correlations were determined for CHI3L1 (rs=0.566, p=0.012) and HGF 
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(rs=0.642, p=0.004) in POAG, these did not pass correction for multiple testing. No 
significant correlations were obtained between age and other analytes (all p≥0.05). 
 
Table 3.3 Correlation of measured analytes to age for non-glaucomatous cataract and 
POAG samples 
 Cataract  POAG 
Analyte rs p-value N  rs p-value N 
CHI3L1 -0.066 0.794 18  0.566 0.012 19 
FLRG 0.475 0.065 16  0.706 0.0007 19 
HGF 0.170 0.662 9  0.642 0.004 18 
MIF 0.404 0.135 15  0.159 0.570 15 
p-selectin -0.756 0.835 9  0.500 0.060 15 
uteroglobin 0.555 0.022 17  0.805 <0.0001 18 
Correlations of normalised analyte concentrations to age were 
determined using Spearman’s rank correlation. Following 
correction for multiple testing using Bonferroni’s method, a p-
value of <0.0017 was considered significant (highlighted in 
bold). rs: Spearman correlation coefficient. N: number of 
correlation pairs. 
 
 
3.4.2 HGF correlated significantly with POAG disease duration since commencing 
treatment 
Analyte concentrations were also assessed for correlations with CDR, IOP, PSD and 
MD for both patient groups, and with disease duration since commencing treatment 
in POAG only (Table 3.4 and Appendix 4-7). A significant correlation was determined 
between HGF and disease duration (rs=-0.723, p=0.0007, Table 3.4). Further 
correlations with disease duration were determined for CHI3L1 and FLRG (rs=-0.555, 
p=0.014 and rs=-0.673, p<0.002, respectively, Table 3.4), and CHI3L1 correlated 
with CDR in cataract (rs=-0.539, p=0.021, Appendix 5), however, they did not pass 
correction for multiple testing (adjusted p-value threshold =0.0017). No correlations 
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were obtained between IOP (Appendix 4), MD (Appendix 6) or PSD (Appendix 7) and 
any analyte for either patient group. 
 
Table 3.4 Correlation of measured analytes to disease duration for POAG samples 
Analyte rs p-value N 
CHI3L1 -0.555 0.014 19 
FLRG -0.673 0.002 19 
HGF -0.723 0.0007 18 
MIF -0.306 0.246 15 
p-selectin -0.312 0.226 15 
uteroglobin -0.377 0.123 18 
Correlations of normalised analyte 
concentrations disease duration (in 
years since commencing treatment) 
were determined using Spearman’s rank 
correlation. Following correction for 
multiple testing using Bonferroni’s 
method, a p-value of <0.0017 was 
considered significant (highlighted in 
bold). rs: Spearman correlation 
coefficient. N: number of correlation 
pairs 
 
 
3.5 DISCUSSION 
In this present study, aqueous humour samples were collected and analysed from 19 
POAG and 18 non-glaucomatous cataract patients as controls. Out of the 30 analytes 
measured, 6 were quantified in sufficient samples to allow for further analysis 
(CHI3L1, FLRG, HGF, MIF, p-selectin and uteroglobin), some of which have not 
previously been assessed with regards to eye physiology or disease. The 
concentrations obtained for HGF and MIF are consistent with existing literature (103, 
114, 240) and to the best of our knowledge, no quantitative measures of CHI3L1, 
FLRG, p-selectin or uteroglobin have been reported in aqueous humour. Four of these 
proteins are directly linked to inflammation: p-selectin and MIF are both pro-
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inflammatory mediators, with p-selectin mediating leukocyte-endothelium adhesion 
(241), and MIF suppressing the anti-inflammatory and immunosuppressive effects of 
glucocorticoids (242). CHI3L1 exerts its pro-inflammatory effects at least in part by 
inhibiting apoptosis of T-cells, macrophages and eosinophils (243). In contrast, 
uteroglobin has anti-inflammatory effects (244, 245). Furthermore, HGF is involved 
in tissue repair (114) and FLRG acts as an inhibitor to members of the TGFβ 
superfamily (246). Whilst no significant differences were found between normalised 
analyte concentrations, significant correlations of specific analytes with disease 
descriptors were obtained, which are discussed below. 
 
A positive correlation was determined for uteroglobin with age in POAG but not 
cataract samples, which may indicate an increased need for anti-inflammatory 
activity in the ageing glaucomatous TM. Uteroglobin is primarily known for its 
association with various allergic and inflammatory lung diseases (247), where it 
exerts an anti-inflammatory effect by supressing various inflammatory mediators, 
including INFγ, PLA2 and TNFα (244, 245). In addition, uteroglobin plays a protective 
role against oxidative stress (248). In eosinophilic chronic rhinosinusitis, uteroglobin 
suppresses the expression of pro-inflammatory CHI3L1 (249). CHI3L1 is a commonly 
used TM cell marker (250-252), although it is only expressed by TM cells in the most 
anterior and posterior regions of the TM tissue (251), which may reflect areas subject 
to the greatest levels of tissue remodelling within the TM. Interestingly, in this study, 
uteroglobin and CHI3L1 correlated in the POAG group but not in the cataract group 
(POAG p=0.006, rs=0.624; cataract p=0.126, rs=0.387), which may suggest that a 
similar mechanism could be occurring in POAG, however, this correlation did not pass 
correction for multiple testing. 
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HGF levels were negatively associated with disease duration since commencing 
treatment in POAG samples, indicating a reduction of HGF over time, which may be 
linked to or independent from treatment for hypertension. HGF plays a role in tissue 
repair and is therefore closely linked to inflammation (114). HGF stimulates 
proliferation, migration and differentiation of many cell types, including TM cells 
(253), and can stimulate MMP activity in endothelial cells (254). In this study, the 
number of samples where HGF was above a set threshold of detection was analysed 
between the POAG and cataract group (Table 3.2, p=0.003); whilst this comparison 
did not pass correction for multiple testing, the result is in line with published 
literature, showing a significant increase in HGF in glaucomatous aqueous humour in 
relation to cataract samples (114). It has been suggested that elevated HGF levels in 
glaucomatous aqueous humour may play a compensatory role, by increasing aqueous 
humour outflow, or aiding in repairing TM damage (114). The correlation suggests 
that this compensation may be lost over time. 
 
Similar to uteroglobin, FLRG correlated positively with age in POAG but not cataract. 
FLRG is a secreted glycoprotein highly homologous to follistatin (255) that binds to 
and thereby inactivates members of the TGFβ superfamily, including activin A and 
BMP2, by disabling their ability to interact with cell surface receptors (246). 
Interestingly, whilst FLRG was measurable, follistatin was not detected in any of the 
samples analysed in this study. Within the anterior segment, FLRG may be involved 
in the regulation of BMP2-induced calcification of the trabecular ECM, which has been 
suggested to occur with age and to be more prominent in glaucomatous TM (227). 
The correlation of FLRG with age may indicate a greater need for BMP2 inhibition, 
due to increased calcification. BMP2-induced calcification of the TM has been shown 
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to directly lead to elevated IOP in a POAG rat model (227) and also agrees with 
existing reports of increased TM stiffness in POAG (193). 
 
Whilst several correlations were determined between analytes and disease 
descriptors at a significance threshold of p=0.05, six out of nine did not pass 
correction for multiple testing (adjusted p=0.0017) but may do so in other 
appropriately powered studies. Although this study did not include a replication 
cohort, each analyte measured was selected from either discovery-based proteomic 
studies or immunoassay-based results reported by other groups (75, 103, 111, 112, 
114, 236, 237). Despite this, we were unable to detect many of the proteins included 
in this study at levels above the lower limit of our standard curve. Aside from technical 
limitations of our chosen multiplex immunoassay, contributing factors may include 
the variation in proteins identified across multiple proteomic studies (75, 232), as 
well as the wide spread of specific analyte concentrations observed between aqueous 
humour samples from different individuals, as reported in some studies (256). 
 
It is important to note that some topical treatments commonly used to treat ocular 
hypertension, such as Latanoprost and Brimonidine, may contribute to aqueous 
inflammation (257, 258). Whilst the potential effects of such medication on the 
protein concentrations discussed here are not specifically known, altered aqueous 
humour concentrations of other proteins have been reported (217). Although there 
were no differences between the normalised analyte concentrations measured in 
POAG and cataract for the six analytes studied here, the potential contributions from 
patient medications to the associations reported here cannot be excluded. 
 
Chapter 3 
3.6 CONCLUSION 
In conclusion, this study has expanded our knowledge of aqueous humour 
composition by providing quantitative measures for four proteins previously 
undetermined for aqueous humour. The correlations of uteroglobin and FLRG with 
age in POAG may suggest an increased need for compensation of inflammatory and 
calcifying activity in the ageing glaucomatous TM to maintain functionality, but at 
present it is unclear whether these proteins play a causative or compensatory role. If 
any or all of these proteins are to have clinical utility, be it as a diagnostic biomarker 
or therapeutic target, further research is needed to define their contributions to TM 
cell physiology, particularly in respect to aqueous humour inflammation and TM 
outflow resistance, and to determine if these proteins have roles in the onset and 
progression of POAG. 
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 MOLECULAR AND FUNCTIONAL CHARACTERISATION OF 
PRIMARY HUMAN TRABECULAR MESHWORK CELLS AND 
THE EFFECT OF UTEROGLOBIN ON TRABECULAR 
MESHWORK CONTRACTION IN VITRO 
 
4.1 ABSTRACT 
4.1.1 Purpose 
Our previous study of aqueous humour composition in POAG identified uteroglobin 
as a protein of interest, due to the significant correlation determined between 
uteroglobin concentration and age in POAG but not cataract control aqueous humour 
samples. Whilst little is known about uteroglobin function, the literature indicates a 
possible role in the regulation of TM contraction, thus affecting aqueous humour 
outflow. We hypothesised that treating TM cells in a 3D collagen gel with recombinant 
uteroglobin would reduce their contractibility. 
 
4.1.2 Methods 
Commercial primary human TM cells (pHTMCs) were characterised by analysis of TM 
marker gene expression (AQP1, CHI3L1, MGP, MMP3, MYOC and TIMP2), increased 
myocilin expression in response to 3 and 5-day Dexamethasone exposure (100 and 
500 nM) and collagen contraction. Expression of uteroglobin receptors FPR2 and 
LMBR1L was assessed using quantitative polymerase chain reaction (qPCR) and 
immunofluorescence. pHTMCs treated with 1 or 2 g/ml uteroglobin were embedded 
in collagen gels and contraction was monitored using photography at 6, 12, 24, 36, 48, 
72 and 96 hours. Both subconfluent and 7-day contact-inhibited pHTMCs were tested. 
Treatment with ROCK inhibitor Y-27632 (100 M) was used to inhibit contraction, 
and HeLa cells and human neonatal dermal fibroblasts (HDFn) were used as control 
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cell lines. Collagen gel contraction was quantified using ImageJ and significance was 
assessed using two-way ANOVA in Prism6. Experiments were conducted in triplicate 
and performed three times (n=3). 
 
4.1.3 Results 
All TM marker genes tested were expressed by pHTMCs and treatment with 
Dexamethasone led to a 25-fold increase in myocilin expression compared to vehicle 
control (p<0.05). Over the 96-hour period, subconfluent pHTMCs contracted the 
collagen gels by 67.0% and contact-inhibited pHTMCs by 62.7%, both comparable to 
HDFn at 71.3% contraction. Addition of Y-27632 significantly reduced contractibility 
of all cell types (p≤0.0001) except HeLa cells. These assays confirmed known 
characteristics of pHTMCs. Of the uteroglobin receptors tested, LMBR1L was detected 
by qPCR and confirmed with immunofluorescence. The impact of uteroglobin 
treatment on contraction was not statistically significant at the concentrations tested. 
 
4.1.4 Conclusions 
No effect of uteroglobin on pHTMC contractibility was found under the conditions 
tested. Additional experiments such as phospholipase A2 (PLA2) activity, TGM2 
activity, and phagocytosis assays are needed to understand the effect of uteroglobin 
on TM cell function. Uteroglobin is a known inhibitor of PLA2 activity, which is 
involved in TM contraction. Furthermore, uteroglobin has been shown to alter 
phagocytic activity of activated neutrophils and potentially inhibits TGM2’s ability to 
cross-link ECM proteins. 
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4.2 INTRODUCTION 
Elevated IOP is a primary risk factor for glaucoma (4) and the focal point of all current 
treatment strategies (259). The majority of aqueous humour drains through the 
conventional outflow pathway, which consists of the TM and Schlemm’s canal (67). 
The TM is a complex connective tissue consisting of intricate ECM structures covered 
by TM cells (118). The TM’s primary role is to regulate aqueous humour outflow 
resistance, which is achieved by continuous remodelling of the ECM (68, 69), 
alterations to TM cell tone and shape via the actomyosin system to affect the geometry 
of the outflow pathway (reviewed by Tian et al. (133)), and phagocytosis of debris to 
prevent pathway blockage (142, 158, 260). These actions are not stand alone, 
however, as contraction of scleral spur and ciliary muscle cells also affects the overall 
architecture of the TM and thus outflow resistance (129). In POAG, TM dysfunction 
causes impairment of the outflow facility, which results in increased aqueous humour 
outflow resistance and thus a build-up of IOP. Whilst many potential mechanisms 
have been investigated, the onset and progression of TM dysfunction and POAG are 
yet to be fully understood.  
 
Uteroglobin, also known as clara cell protein, CC10, CC16 or CCSP, is a steroid-
inducible, homodimeric protein of 16 kDa that contains a hydrophobic pocket (261). 
Whilst uteroglobin is best known for its presence in the uterus and lung, research has 
established that uteroglobin is secreted by many tissues (262). Uteroglobin has been 
well studied with regards to protein structure and gene expression regulation, yet its 
physiological roles are only partially understood. 
Chapter 4 
Uteroglobin is a multifunctional protein that affects many cell processes. Known 
functions include binding and possibly sequestering a variety of hydrophobic ligands, 
inhibition of inflammation, and protection against oxidative stress (263-266). 
Uteroglobin’s best studied function lies in its ability to inhibit PLA2 activity (267-269), 
an enzyme that is present in the TM and affects aqueous humour outflow through TM 
contraction. Specifically, inhibition of calcium-independent PLA2 results in cellular 
relaxation in vitro and increased aqueous humour outflow facility in perfused 
enucleated porcine eyes (270). 
 
It is unclear how uteroglobin imparts its effects on cellular function. Several putative 
receptors and uteroglobin binding proteins have been identified (265, 271-274), and 
the detection of internalised uteroglobin in several studies (272, 275, 276) suggests 
cellular entry via receptor-mediated endocytosis as one mode of signalling. 
Uteroglobin has a high affinity for lipocalin-1 receptor (LMBR1L, also known as LIMR) 
(271), which presents itself as a potential endocytic receptor for uteroglobin. As 
LMBR1L mediates endocytosis of lipocalin-1 (277) and -lactoglobulin (278), both of 
which share high structural similarity with uteroglobin, it is conceivable that LMBR1L 
may also mediate cellular uptake of uteroglobin. Specific uteroglobin interaction has 
also been demonstrated with membrane receptor FPR2 and research suggests that 
uteroglobin interaction with FPR2 may elicit an anti-inflammatory response (279). 
 
Overall, whilst uteroglobin has been detected in aqueous humour samples from both 
glaucomatous and control subjects (280), the published literature contains no 
information regarding uteroglobin’s potential role in ocular physiology. Based on the 
existing literature, we hypothesised that uteroglobin may inhibit TM cell contraction 
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via PLA2 inhibition. Thus, the aim of this study was to characterise a commercial 
human TM cell strain derived from non-glaucomatous post-mortem eyes and 
subsequently test whether application of exogenous uteroglobin affects cell 
contraction. 
 
4.3 MATERIALS & METHODS 
4.3.1 pHTMC culture 
pHTMCs were obtained from ScienCell Research Laboratories (Carlsbad, CA). Plastic 
ware (Greiner Bio-one, Kremsmünster, Austria) used to culture pHTMCs was coated 
with a 0.1% gelatine solution (powdered porcine gelatine in sterile water; Sigma-
Aldrich, St. Louis, MO) for 2 hours at room temperature prior to use (281). pHTMCs 
were cultured in glucose-free Dulbecco’s modified Eagle’s medium (DMEM) 
containing 4 mM glutamine, supplemented with 10% foetal bovine serum (FBS), D-
glucose (final concentration 2.75 g/l) (282), and antibiotic-antimycotic (10’000 
units/mL penicillin, 10’000 g/ml streptomycin and 25 g/ml Gibco amphotericin B), 
all from Thermo Fisher (Waltham, MA) (281, 283). This medium is referred to as TM 
growth medium below. Basic fibroblast growth factor (bFGF; Thermo Fisher) was 
added to daily media aliquots at 5 ng/ml (283). Cells were maintained at 37C and 
5% CO2 and the medium was replaced every 2-3 days. Once 90% confluence was 
reached, cells were passaged using trypsin/EDTA and trypsin neutralising solution 
(both Lonza Walkersville Inc., Walkersville, MD) following the reagent protocol. Once 
resuspended, cells were plated at a minimum seeding density of 5’000 cells/cm2. Cell 
cultures up to passage 6 were used for experimentation. For some experiments, as 
detailed below, pHTMCs were maintained at 100% confluence for seven days prior to 
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the assay, as contact-inhibited pHTMCs have been reported to more closely reflect the 
behaviour of TM cells in vivo (71, 284). Supplementation with bFGF was omitted 
during this 7-day period and the medium was replaced every other day. 
 
4.3.2 HDFn and HeLa cell culture 
HDFn (Thermo Fisher) and HeLa cells (gift from Associate Professor Liza Snow) were 
grown in TM growth medium (glucose-free DMEM, 4 mM glutamine, 10% FBS, 2.75 
g/l D-glucose, and antibiotic-antimycotic (10’000 units/ml penicillin, 10’000 g/ml 
streptomycin and 25 g/ml Gibco amphotericin B)) without bFGF supplementation 
and using uncoated plastic ware. The cells were maintained at 37C and 5% CO2 and 
the medium was replaced every 2-3 days. Cultures were passaged at 80-90% 
confluence using trypsin/EDTA and trypsin neutralising solution (both Lonza) and 
seeded at a split ratio of 1:4 to 1:8. 
 
4.3.3 RNA extraction 
RNA was extracted from subconfluent (approx. 90% confluence) and contact-
inhibited pHTMCs, the latter of which were maintained at confluence in the absence 
of bFGF supplementation for seven days prior to RNA extraction. Cells were washed 
in Hank’s balanced salt solution (HBSS; Thermo Fisher), disrupted in RLT buffer, and 
homogenised using the QIAshredder homogenizer (both Qiagen, Hilden, Germany). 
Total RNA was extracted in accordance with the manufacturer’s instructions using the 
RNeasy Mini Kit with DNAse digestion (Qiagen). RNA was eluted in 30 l RNase-free 
water and stored at -80C. RNA extraction from each condition was performed three 
times (n=3). 
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4.3.4 cDNA synthesis 
RNA purity was assessed using the Experion StdSens Analysis kit (Bio-Rad 
Laboratories, Inc. Hercules, CA) with a minimum RNA integrity number >9 
considered acceptable. RNA concentration was measured with the Qubit RNA BR 
assay kit (Invitrogen). The Omniscript RT kit (Qiagen) was used to reverse transcribe 
one g total RNA with random primer 9 (15.5 M final concentration; New England 
Biolabs, Ipswich, MA) and RNase inhibitor (8 units/reaction; Qiagen). Prior to cDNA 
synthesis, RNA aliquots were heated to 65C for 5 minutes to reduce secondary 
structure. 
 
4.3.5 Quantitative PCR and analysis 
qPCR experiments were performed using TaqMan fast advanced master mix and 
TaqMan gene expression probes (all Thermo Fisher). All probes used to assess TM 
marker gene expression, as well as HPRT1 (used for normalisation), are listed in 
Appendix 8. Probes for uteroglobin, HGF, and their respective receptors are listed in 
Appendix 9. All cDNAs were diluted 1:10 with nuclease-free water prior to qPCR 
setup. Samples were run in triplicate on a StepOnePlus real-time PCR system (Thermo 
Fisher) and data points above 35 cycles (threshold cycle; CT) were considered 
undetermined. Furthermore, values more than 0.2 CT above or below the remaining 
readings were deemed outliers and removed prior to analysis. Mean CT values from 
triplicate wells were normalised against HPRT1 as the endogenous reference gene 
and the results were quantified using the comparative CT method. 
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4.3.6 Immunocytofluorescence 
pHTMCs were passaged as described above, resuspended in TM growth medium with 
bFGF supplementation, and seeded into 4-well chamber slides at a density of 5’000 
cells/cm2. The media was replaced every other day until a confluency of 60-80% was 
reached. All cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) and cells 
probed for intracellular epitopes were permeabilised with cold methanol prior to 
immunostaining. The cells were blocked in 5% normal goat serum (Cell Signalling 
Technology, Inc., Danvers, MA) for one hour at room temperature, followed by 
overnight incubation with primary antibodies diluted in phosphate-buffered saline 
(PBS; extracellular epitope) or PBS/0.3% Triton X-100 (intracellular epitope) at 4C 
(see Appendix 10 for details). Cells were then stained with fluorochrome-conjugated 
secondary antibodies (Appendix 11) at room temperature for two hours and counter-
strained with Hoechst 33342 (Thermo Fisher) and in some instances Alexa Fluor 488 
Phalloidin (Cell Signalling Technologies, Inc.) according to manufacturers’ 
instructions prior to mounting with SlowFade Gold Antifade medium (Life 
Technologies). Negative control slides were prepared in the same manner but were 
incubated with PBS alone instead of the primary antibody. Images were taken on an 
Olympus FV1200 confocal microscope (Tokyo, Japan) and processed in Photoshop 
(version 12.0) to adjust global image brightness and contrast. Magnification and 
exposure times are indicated with each figure. 
 
4.3.7 Dexamethasone-stimulated myocilin assay 
The method for Dexamethasone-stimulated myocilin upregulation by cultured TM 
cells was adapted from Resch et al. (285). Briefly, pHTMC cultures were maintained 
at confluence for seven days prior to treatment with either 100 or 500 nM 
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Dexamethasone (Sigma-Aldrich), or 0.1% absolute ethanol (VWR, Radnor, PA) as a 
vehicle control, in TM growth medium without bFGF. Treatments were administered 
daily by direct addition to conditioned media. On the third and fifth day of treatment, 
total RNA was extracted and analysed as previously described to assess myocilin gene 
expression. The time points for sample collection were selected on the basis that 
myocilin protein upregulation is detectable after two days of Dex treatment (285, 
286). In addition, conditioned medium was harvested and stored at -80C for Western 
blot analysis. The Pierce BCA protein assay kit (Thermo Fisher) was used to 
determine sample protein concentrations. Equal amounts of protein (15 g) were run 
on SDS-PAGE gels (4-15% Mini-PROTEAN TGX Precast gels; Bio-Rad) and transferred 
to PVDF membranes using the Trans-Blot Turbo transfer system (Bio-Rad). The Page 
Ruler Plus pre-stained protein ladder (Thermo Fisher) was run with the samples. The 
membrane was blocked in 5% skim milk powder in Tris-buffered saline pH7.6 + 0.1% 
Tween20 (TBST) at room temperature for 60 minutes, followed by overnight 
incubation with a polyclonal antibody to myocilin (PAH58Hu01; 1:1000 dilution; 
Cloud-Clone Corp., Katy, TX) in 5% skim milk powder in TBST at 4C. Subsequently, 
the membrane was incubated with HRP-conjugated anti-rabbit antibody (CST# 7074; 
1:2000 dilution; Cell Signalling Technology, Inc.) at room temperature for one hour. 
Chemiluminescent detection was performed after a 5-minute incubation with 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher). 
 
4.3.8 MTT assay 
Cell survival in the presence of recombinant uteroglobin (R&D Systems, Minneapolis, 
MN) was assessed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide (MTT) assay, using the Thermo Fisher Vybrant MTT cell proliferation assay 
kit protocol. pHTMCs were cultured in phenol-free media and optimal cell seeding 
density was determined by means of cell titration. For subsequent experiments, cells 
were seeded at 7.3 x104 cells/cm2 in 96-well plates (75% confluence) in 100 l 
phenol-free TM growth media and left to adhere overnight. Cells received a one-off 
treatment with recombinant uteroglobin at 0.05, 0.5, 1.0, 2.0, or 5 g/ml, 1% HBSS as 
vehicle control, or 0.5% Triton X-100 (Sigma-Aldrich) as a negative control. Cell 
survival was assessed at 24, 48, and 72 hours of recombinant uteroglobin exposure. 
After incubation with 12 nM MTT, DMSO (Sigma-Aldrich) was added for 10 minutes 
at 37C to dissolve the resulting formazan particles for measurement at 570 nm, with 
a reference wavelength of 650 nm, on a Tecan Infinite 200Pro (Tecan Trading AG, 
Männedorf, Switzerland). Cells treated with 0.5% Triton X-100 were used as a 100% 
death control and untreated cells as a 100% live control, which were used to calculate 
cell viability. Each variable was assessed in triplicate and the experiment was 
performed twice (n=2). 
 
4.3.9 Collagen gel contraction assay 
The collagen gel contraction assay was performed as previously described (287-289), 
with minor modifications. The wells of 24-well cell culture plates were coated with 
1% bovine serum albumin (BSA) for one hour at 37C. Cultured pHTMC, HDFn and 
HeLa cells were trypsinised as described above and resuspended in TM growth 
medium without bFGF at 2.2x106 cells/ml. Cell treatments with ROCK inhibitor Y-
27632 (100 M; StemCell Technologies, Inc., Vancouver, Canada), recombinant 
uteroglobin (1 and 2 g/mL; R&D Systems), or 1% HBSS as vehicle control, were set 
up prior to preparing the collagen mix. Rat tail collagen type I (Thermo Fisher), 10x 
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DMEM (Sigma-Aldrich), 10x PBS (Thermo Fisher), cell suspension, and water were 
mixed on ice to obtain a final concentration of 1.9 mg/ml collagen and a final cell 
density of 2x105 cells/ml. 1N sodium hydroxide was added as described in the manual 
for rat tail collagen. The mixture (0.5 ml) was added to each BSA-coated well and gel 
formation was induced at 37C for 90 minutes. Subsequently, TM growth medium 
supplemented with the same concentrations of Y-27632, uteroglobin, and vehicle 
control as the cell treatments (0.5 ml, without bFGF) was added to the gels. After one 
hour, a microspatula was used to release the gels from the walls of the culture wells. 
The gels were photographed at 0, 6, 12, 24, 36, 48, 72 and 96 hours and a reduction in 
surface area was assessed using ImageJ (version 1.49v). A measurement scale was 
included in each photograph. Each experiment was performed in triplicate and 
repeated three times (n=3). HDFn and HeLa cells were used as a positive and negative 
control for contraction, respectively, and treatment with Y-27632 was used as a 
control for cell contraction inhibition. 
 
4.3.10 Statistical analyses 
All statistical analyses were conducted with Prism 6 (GraphPad Software, San Diego, 
CA). Gene expression was assessed with two-tailed, unpaired T-tests for individual 
markers and 2-way ANOVAs with Tukey post-test were used to test significance for 
myocilin PCR, contraction, and MTT assays. A p-value  0.05 was regarded as 
statistically significant. 
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4.4 RESULTS 
4.4.1 Characterisation of commercial pHTMCs 
Prior to testing the impact of uteroglobin on pHTMC behaviour in vitro, the suitability 
of commercial pHTMCs obtained from ScienCell Research Laboratories, Inc. was 
assessed. Expression of known TM marker genes AQP1, CHI3L1, MGP, MMP3, MYOC 
and TIMP2 (71) was analysed, and Dexamethasone-stimulated myocilin secretion 
(285) and collagen contraction (287-289) assays were used to assess cell function. 
 
4.4.1.1 pHTMCs express known trabecular meshwork marker genes 
Expression of all TM markers tested was confirmed by means of qPCR in both 
subconfluent and contact-inhibited pHTMCs cultured in vitro (Figure 4.1A). Whilst 
gene expression did not differ significantly between the two growth conditions tested, 
greater variability between repeats was seen in subconfluent cultures. Expression of 
AQP1 and CHI3L1 was confirmed by immunofluorescent staining (Figure 4.1B), and 
both were expressed uniformly by all pHTMCs present. Immunofluorescence was 
performed using subconfluent cultures to allow the identification of individual cells. 
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Figure 4.1 TM marker expression in pHTMCs in vitro. A) Subconfluent (S; blue) and 
contact-inhibited (CI; orange) pHTMCs were assessed for expression of TM markers 
relative to HPRT1 using qPCR. Statistical significance was tested by unpaired T-tests for 
individual genes; no significant differences were determined. Gene expression was 
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measured in triplicate and the experiment was performed three times (n=3). Data 
shown as mean  SD. B) Subconfluent pHTMCs were stained against selected TM 
markers (AQP1 and CHI3L1; red) and nuclei with Hoechst (blue). Images were taken 
on a confocal microscope using a 10x objective with 3.6x zoom and an exposure time of 
2 s/pixel. The scale bar corresponds to 20 m. 
 
4.4.1.2 Stimulation with Dexamethasone increases myocilin expression in pHTMCs 
in vitro 
Contact-inhibited pHTMC cultures treated with 100 or 500 nM Dexamethasone for 
three days presented a statistically significant increase in myocilin gene expression 
(p  0.05) compared to cultures treated with vehicle alone (0.1% ethanol; Figure 4.2). 
This increase in myocilin mRNA did not change significantly when Dexamethasone 
exposure was increased to five days. An attempt was made to detect secreted myocilin 
in conditioned media from Dexamethasone-treated pHTMC cultures by Western 
blotting (Appendix 12). However, a positive signal coinciding with the expected 
molecular weight of myocilin was obtained from naïve media making this analysis 
inconclusive. 
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Figure 4.2 Effect of Dexamethasone (Dex) treatment on myocilin expression in pHTMCs 
in vitro. Myocilin gene expression levels relative to HPRT1 in pHTMCs treated with 
vehicle control (0.1% ethanol, black), 100 nM Dex (blue), or 500 nM Dex (orange) in 
vitro. Gene expression was assessed by qPCR after 3 and 5 days of treatment. Statistical 
significance was assessed using two-way ANOVA with Tukey post-test, * indicates p  
0.05. The experiment was performed three times (n=3). Data are shown as mean  SD. 
 
4.4.1.3 pHTMCs embedded in collagen I contract and treatment with ROCK inhibitor 
Y-27632 blocks this action 
Cellular contraction was assessed by seeding pHTMCs in a 3D gel made with collagen 
I and recording changes in surface area at 6, 12, 24, 36, 48, 72, and 96 hours. Both 
subconfluent and contact-inhibited pHTMCs were tested, and HDFn and HeLa cell 
cultures served as controls. Example photographs of gels at 0, 24, and 96 hours are 
shown in Figure 4.3A for all cell types assessed. Over the 96-hour period, subconfluent 
pHTMCs contracted the collagen gels by 67.0% (p  0.0001) and contact-inhibited 
pHTMCs by 62.7% (p  0.0001; Figure 4.4A) when compared to 0 hours. These results 
are comparable to HDFn cultures, which were used as a positive control and yielded 
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71.3% contraction (p  0.0001). The contraction observed for HeLa cells, which 
served as a negative control, was negligible (4.0%; p > 0.05). By six hours, the level 
of contraction seen in both subconfluent and contact-inhibited pHTMCs differed 
significantly from HeLa cell contraction (p  0.05). Furthermore, a statistically 
significant distinction between pHTMC and HDFn contraction was seen from 36 hours 
onwards (p  0.05). At no time point did the extent of contraction differ significantly 
between subconfluent and contact-inhibited pHTMCs (p > 0.05). 
 
With the exception of HeLa cells, the addition of 100 M Y-27632 significantly 
reduced collagen gel contraction over the 96-hour period for all cell types tested 
(Figure 4.4B). Representative photographs of these gels are shown in Figure 4.3B. At 
96 hours, in comparison to untreated cells, subconfluent pHTMCs reached just 15.0% 
contraction (p=0.002), contact-inhibited pHTMC contraction was 18.9% (p=0.003) 
and HDFn contraction was reduced to 15.3% (p=0.003). HeLa cells displayed no 
contraction when treated with Y-27632 (p > 0.05). 
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Figure 4.3 Representative photographs of pHTMC, HDFn, and HeLa cells contracting 3D 
collagen gels. Images of collagen gel contraction by subconfluent (S) and contact-
inhibited (CI) pHTMCs, HDFn, and HeLa cells A) in the absence and B) presence of Y-
27632 at 0, 24, and 96 hours. 
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Figure 4.4 Contractibility of pHTMC, HDFn, and HeLa cells embedded in a 3D collagen 
gel. Collagen gel contraction by subconfluent (S) and contact-inhibited (CI) pHTMCs, 
HDFn, and HeLa cells A) in the absence and B) in the presence of 100 M Y-27632 was 
determined by measuring changes in gel surface area over 96 hours, presented as % 
contraction relative to 0 hours. Data shown as mean  SD (n=3). To minimize 
complexity, statistical significance has been omitted from the figure and is presented in 
the body of text. 
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4.4.2 Effect of exogenous uteroglobin on pHTMCs in vitro 
Chapters 2 and 3 of this thesis involved the study of various protein concentrations in 
glaucomatous aqueous humour and correlation of these to POAG disease descriptors. 
Chapter 3 highlighted uteroglobin and HGF as two proteins of potential therapeutic 
or diagnostic use, based on the significant correlations determined with age and 
disease duration, respectively. To further investigate any potential roles in TM 
physiology, this study aimed to select HGF or uteroglobin, based on initial 
experiments, and investigate whether treatment of pHTMCs in vitro affects TM cell 
behaviour. To aid with the decision, pHTMCs were assessed for gene expression of 
both factors and their corresponding receptors to determine which protein would be 
more suitable for this study. 
 
4.4.2.1 pHTMCs cultured in vitro express HGF, its receptor MET, and uteroglobin 
receptor LMBR1L, but not uteroglobin or FPR2 
HGF is a well-known growth factor that signals through its receptor MET (290). With 
uteroglobin the signalling pathways appear more diverse and less clearly elucidated. 
Two receptors of interest for this study are LMBR1L and FPR2. LMBR1L has a high 
affinity for uteroglobin and is a potential endocytic receptor for uteroglobin (278). 
FPR2 presents another potential receptor for uteroglobin and this interaction results 
in a tonic inhibition of baseline PLA2 activity (279), although it is unclear if this 
involves uteroglobin internalisation. 
 
Both subconfluent and contact-inhibited pHTMCs were assessed for expression of 
HGF and its receptor MET, as well as uteroglobin and its putative receptors LMBR1L 
and FRP2 using qPCR (Figure 4.5). In both cases, HGF, MET, and LMBR1L were 
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expressed whereas uteroglobin and FPR2 were undetected. No statistically significant 
differences were observed between the two culture conditions. To confirm these 
results, LMBR1L and MET expression were assessed by immunofluorescence using 
phalloidin to counterstain the actin cytoskeleton. Whilst LMBR1L uniformly stained 
all pHTMCs present (Figure 4.6A), the antibody used for MET yielded negative results 
under the conditions tested (Figure 4.6B). As with pHTMC characterisation, 
immunofluorescence was performed using subconfluent cultures to allow for 
identification of individual cells. At this point, a decision was made to focus on 
uteroglobin and subsequent experiments were planned accordingly. 
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Figure 4.5 Gene expression of uteroglobin, HGF, and their respective receptors in 
pHTMCs in vitro. Subconfluent (S; blue) and contact-inhibited (CI; orange) pHTMCs 
were assessed for expression of A) HGF  and its receptor MET  and B) uteroglobin (UG) 
and receptors LMBR1L and FPR2, relative to HPRT1 using qPCR. Statistical significance 
was assessed using unpaired T-tests for individual genes, with p  0.05 considered 
significant. No significant differences were determined. Gene expression was measured 
in triplicate and the experiment was performed three times (n=3). Data are shown as 
mean  SD. 
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Figure 4.6 Immunofluorescent staining for MET and LMBR1L in pHTMCs in vitro. 
Subconfluent pHTMCs were stained for A) LMBR1L (red) and B) MET (red). Phalloidin 
(green) was used to stain actin and nuclei were stained using Hoechst (blue). Images 
were taken on a confocal microscope with a 40x objective and an exposure time of 8 
s/pixel. The scale bar corresponds to 20 m. 
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4.4.2.2 Exogenous uteroglobin does not affect pHTMC viability 
MTT assays were performed to assess the impact of uteroglobin treatment on pHTMC 
viability in vitro. Uteroglobin was tested at 0.05, 0.5, 1.0, 2.0, and 5.0 g/ml in a single 
dose treatment at the start of the assay. No significant negative impact on pHTMC 
viability was observed over the 72-hour period tested (Figure 4.7). Equally, no 
significant differences were determined between the different uteroglobin 
concentrations at any of the time points tested (p > 0.05). The only statistically 
significant differences observed were for pHTMCs treated with 5 g/ml, where MTT 
metabolism was increased at 48 hours and subsequently returned to its previous level 
by 72 hours. Both the difference between 24 and 48 hours and between 48 and 72 
hours resulted in a p-value  0.05. 
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Figure 4.7 Effect of exogenous uteroglobin on pHTMC viability in vitro as determined 
by MTT assays. Subconfluent pHTMCs were treated with vehicle control (1% HBSS) or 
0.05, 0.5, 1.0, 2.0, or 5.0 g/ml uteroglobin (UG). Viability was assessed at 24, 48, and 
72 hours. Each variable was tested in triplicate and the experiment was performed 
twice (n=2). Data are shown as mean  SD. To minimize complexity, statistical 
significance has been omitted from the figure and is presented in the body of text. 
 
4.4.2.3 Effect of exogenous uteroglobin on pHTMC contraction 
The primary aim of this study was to determine whether uteroglobin affects pHTMC 
contraction by inhibiting PLA2. As pHTMCs do not express uteroglobin (Figure 4.5A), 
any effects seen would be the result of extracellular uteroglobin either transmitting a 
signal via a cell surface receptor or entering the cell via receptor-mediated 
endocytosis. To test our hypothesis, subconfluent and contact-inhibited pHTMCs 
were treated with vehicle control, 1.0, or 2.0 g/ml uteroglobin and then seeded in 
3D gels containing collagen I. Gels were photographed at 6, 12, 24, 36, 48, 72, and 96 
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hours to record changes in surface area. Representative images of gels at 0, 24, and 
96 hours are shown in Figure 4.8.  
 
Over the 96-hour period, subconfluent pHTMCs treated with vehicle control, 1.0, and 
2.0 g/ml uteroglobin contracted the collagen gels by 65.1, 68.9, and 72.3%, 
respectively (Figure 4.9A), whereas contact-inhibited pHTMCs treated with vehicle 
control, 1.0, and 2.0 g/ml uteroglobin resulted in 55.8, 58.2, and 56.3% contraction, 
respectively (Figure 4.9B). Neither subconfluent nor contact-inhibited pHTMCs gave 
rise to statistically significant differences between the treatments at any time point 
tested (p > 0.05). 
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Figure 4.8 Representative photographs of collagen contraction by pHTMCs treated with 
uteroglobin. Images of collagen gel contraction by A) subconfluent (S) and B) contact-
inhibited (CI) pHTMCs treated with vehicle control (VC; 1% HBSS), 1.0, or 2.0 g/ml 
uteroglobin (UG) at 0, 24, and 96 hours. 
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Figure 4.9 Effect of exogenous uteroglobin on pHTMC contraction. Collagen gel 
contraction by A) subconfluent (S) and B) contact-inhibited (CI) pHTMCs treated with 
vehicle control (1% HBSS), 1.0, or 2.0 g/ml uteroglobin (UG) was determined by 
measuring changes in gel surface area over 96 hours, presented as % contraction 
relative to 0 hours. The experiment was performed in triplicate and repeated three 
times (n=3). Data are shown as mean  SD. No statistically significant differences were 
found (assessed by 2-way ANOVAs with Tukey’s post-test).  
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4.5 DISCUSSION 
TM cell contraction is one mechanism involved in the control of aqueous humour 
outflow resistance and thus IOP. Specifically, TM cell relaxation leads to an increase 
in aqueous humour drainage through the conventional outflow pathway (129, 133, 
134). Consequently, chemicals that promote TM cell relaxation present a potential 
strategy for relieving ocular hypertension (291), an avenue that has been pursued 
more recently with the development of ROCK inhibitors for therapeutic use (292, 
293). 
 
Prior to assessing the potential effects of uteroglobin on TM cells in vitro, the cell 
strain to be tested was characterised for TM behaviour. Due to a lacking consensus 
regarding TM cell isolation, characterisation, and culture at the time of 
experimentation (recently addressed by Keller et al. (149)), a combination of 
previously described molecular and functional assays was employed to assess the 
suitability of the commercial pHTMC strain for use in this study. The pHTMCs 
expressed all TM markers tested and subconfluent versus contact-inhibited growth 
conditions did not significantly affect gene expression levels. Assessment of selected 
markers by immunofluorescence also indicated a high level of homogeneity within 
the cultures tested. Treatment with Dexamethasone to increase myocilin expression, 
an assay considered critical to TM cell characterisation (149), successfully induced 
myocilin gene expression. However, we were unable to show an increase in cell-
secreted myocilin protein levels, due to a positive signal obtained for myocilin in the 
naïve media. It is unknown whether the immunoreactive signal is due to the presence 
of myocilin in naïve media or the result of a non-specific interaction with a protein of 
similar molecular weight. 
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The contraction assay successfully demonstrated the pHTMCs’ contractile properties, 
which were significantly reduced when treated with Y-27632, an inhibitor that has 
previously been used to block TM cell contraction in vitro (289). While the level of 
contraction observed for pHTMCs was comparable to previously published work 
using human TM cells (289), an extended culturing time frame was required to 
achieve the same level of contraction, with 68% contraction reached by 96 hours in 
our study instead of 24 hours. In comparison, the extent of collagen contraction 
observed in studies using bovine TM cells was markedly lower (287, 288). Given this 
limited evidence in the literature regarding extent and duration of contraction, it is 
impossible to estimate a correct amount and duration for this assay and further 
evidence is required to determine the potential causes for the difference seen 
between Koga et al.’s and our study in regard to duration of contraction. In the 
presence of 100 M Y-27632, no contraction was detectable at 24 hours, matching 
previously published results (289).  
 
Whilst the cell strain characterisation was successful, the juvenile source of these cells 
(24-week old donor) may impact on their behaviour. Thus, the results obtained from 
this study require verification in TM cell cultures derived from adult post-mortem 
eyes, ideally from POAG subjects and age-matched healthy controls. 
 
In a previous study (280), analysis of aqueous humour samples from non-
glaucomatous cataract and POAG patients highlighted several proteins of interest 
with regards to POAG, including HGF and uteroglobin. To determine which protein to 
focus on in this current study, pHTMCs were assessed for expression of these two 
factors and their receptors MET (HGF receptor), LMBR1L, and FPR2 (both 
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uteroglobin receptors). The gene expression results obtained suggest that pHTMCs 
express HGF  but not uteroglobin, which is in agreement with the results gained when 
analysing HGF and uteroglobin concentrations in pHTMC conditioned media 
(unpublished data) as part of our previous study (280). Confirmation of receptor 
expression using immunofluorescence was successful for LMBR1L but not MET. The 
absence of endogenous uteroglobin production and the presence of a potentially 
endocytic receptor for uteroglobin led us to focus on uteroglobin’s potential effect on 
pHTMC behaviour. 
 
One-off treatment with 1 or 2 g/ml recombinant uteroglobin did not result in any 
significant differences in pHTMC contraction when compared to vehicle control 
treated cells and as such, the results of this study are inconclusive. It is possible that 
repeat treatments with uteroglobin or a different concentration are necessary to see 
an effect on cell contraction. The concentrations tested have previously been used 
successfully in an in vitro phagocytosis study using neutrophils (275). Whilst these 
concentrations (equivalent to 62.5 and 125 nM) are substantially lower than the 
micromolar uteroglobin concentration determined by Levin et al. for in vitro PLA2 
inhibition (267), the concentrations of uteroglobin measured in aqueous humour 
(280) are even lower, in the pg/ml range. 
 
The lack of response to uteroglobin treatment may also be due to the cell strain used. 
The TM is a complex tissue consisting of three distinct layers, and questions exist as 
to whether the TM cells in these structures form distinct cell types, specifically the 
cells of the JCT versus the corneoscleral TM, or whether they represent one cell type 
in different biological environments (122, 149, 294, 295). Therefore, the location of 
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TM cell extraction needs to be considered when evaluating in vitro experimental data. 
According to the manufacturer, the cell strain used in this study was isolated from the 
corneoscleral and juxtacanalicular region of a healthy TM, thus potentially presenting 
a heterogeneous cell population. This may or may not be relevant with regards to the 
effects of uteroglobin on contraction. Ideally, the effects of uteroglobin would be 
tested on TM cell strains from adult healthy and POAG eyes. Whilst some laboratories 
have successfully grown TM cells from glaucomatous eyes (189, 296, 297), 
glaucomatous TM cells are generally difficult to culture, due to reduced cell numbers 
and the effects of prolonged treatment with glaucoma medications (149). As an 
alternative, patient-derived induced pluripotent stem cells (iPSCs) could be used to 
model TM cell function in vitro, although the necessary differentiation protocol is yet 
to be fully developed. 
 
Cellular contraction may also be assessed by measuring the formation of actin stress 
fibres, focal adhesions, and phosphorylation of myosin light chain kinase (270). Due 
to the molecular nature of cellular contraction processes, these alternative assays 
would likely provide more sensitive measures for contraction and may thus be able 
to detect differences that are not measurable by means of a collagen gel contraction 
assay.  
 
Further experiments are needed to support the data obtained in this study, including 
the in vitro cell-free testing of recombinant uteroglobin in a PLA2 activity assay to 
ensure its bioactivity. Ideally, a contractile cell line that responds to uteroglobin 
treatment would be used as a positive control. However, this may prove difficult to 
Chapter 4 
achieve due to the lack of knowledge regarding uteroglobin’s signalling pathway and 
detailed physiological function. 
 
Three additional aspects of uteroglobin function are of potential interest with regards 
to POAG and TM dysfunction (summarised in Figure 4.10). Firstly, uteroglobin has 
been reported to enhance phagocytosis of fluorescently-labelled beads in activated 
neutrophils (275). Thus, a phagocytosis assay could be used to assess whether 
uteroglobin treatment has a stimulatory effect on the phagocytic activity of TM cells 
(139).  
 
Secondly, uteroglobin has a high affinity for TGM2 (298), an enzyme which covalently 
crosslinks ECM proteins to increase rigidity and prevent degradation (299). 
According to one in vitro study, TGM2 protein levels and enzymatic activity are 
elevated in glaucomatous TM cells compared to normal TM cells (180). Antiflamin, a 
peptide derived from uteroglobin, has been shown to inhibit TGM2 (300). Thus, it is 
conceivable that uteroglobin may also have an inhibitory effect on TGM2 activity, 
which would be beneficial in POAG, where ECM crosslinking and rigidity contribute 
to TM dysfunction and IOP elevation. Furthermore, TGM2 can stimulate PLA2 function 
(300), thus inhibition of TGM2 by uteroglobin would additionally provide an indirect 
pathway for PLA2 inhibition, resulting in TM relaxation and enhanced aqueous 
humour outflow.  
 
Thirdly, uteroglobin can bind to fibronectin in a highly specific manner through a 
heparin-binding site (301). Whilst two main heparin-binding sites are known within 
fibronectin (HepI and HepII), Chowdhury et al (301) did not specify which heparin-
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binding site uteroglobin interacts with. Fibronectin is an abundant component of the 
TM ECM (302) and the HepII domain in fibronectin has been shown to reduce TM 
contractility (303) and increase outflow facility in perfused anterior segments (304, 
305), highlighting the relevance of HepII in the regulation of outflow resistance. This 
process is thought to involve members of the rho GTPase family (304), which control 
TM contractility (291). Fibronectins can be crosslinked to each other as well as to 
other elements of the ECM by TGM2, a process stimulated by TGF2 (179). 
Interestingly, TGM2-fibronectin complexes stimulate rho GTPase signalling (306, 
307), suggesting that the interaction between TGM2 and fibronectin may cause TM 
cell contraction and consequently reduced outflow facility (291, 308). In addition, 
TGM2 can also covalently crosslink uteroglobin to fibronectin. The specific interaction 
between uteroglobin and fibronectin has been shown to inhibit adhesion and 
migration of human endothelial cells in vitro (309). Collectively, this information 
suggests that uteroglobin interaction with fibronectin could influence TM cell 
contraction and thus affect aqueous humour outflow. 
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Figure 4.10 Diagram illustrating how uteroglobin may influence aqueous humour 
outflow through the trabecular meshwork, through interactions with tissue 
transglutaminase (TGM2), calcium-independent phospholipase A2 (iPLA2), fibronectin, 
and trabecular meshwork cell phagocytosis. Interactions that are uncertain are 
highlighted with a question mark (?). 
 
In conclusion, treatment of pHTMCs with a single dose of exogenous uteroglobin did 
not affect cell contractibility at the concentrations tested. Additional experiments, 
such as PLA2 activity, TGM2 activity, and phagocytosis assays, are needed to elucidate 
the role of uteroglobin in TM cell function. 
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 GENERAL DISCUSSION AND CONCLUSION 
 
5.1 PURPOSE AND AIMS OF THE RESEARCH 
The TM plays a key role in regulating IOP, which in turn is critical for eye health and 
function. Whilst loss of appropriate pressure control is attributed to a dysfunctional 
TM, our knowledge of the cellular mechanisms involved is incomplete. The purpose 
of the research presented in this thesis was to increase our understanding of TM 
dysfunction in POAG, first by assessing changes in aqueous humour protein 
composition in clinical POAG and cataract control samples, and secondly by 
investigating the potential effects of one of the identified proteins on TM cell function 
using an in vitro cell model. 
 
5.2 SUMMARY OF NOVEL FINDINGS AND IMPLICATIONS FOR THE FIELD 
The aqueous humour studies presented in chapters 2 and 3 provide new insights into 
the altered protein composition of aqueous humour in POAG compared to cataract 
control samples. Whilst previous studies have quantified concentrations of various 
MMPs and TIMPs in aqueous humour and calculated direct ratios (pg/ml) (93, 97, 99, 
100), none have performed a stochiometric analysis to investigate their molar ratios 
and determine potential relative imbalances in MMP inhibition. This is an important 
consideration, given that the ratio of enzyme to inhibitor determines enzyme activity 
and is thus more relevant than overall concentration. The imbalances determined in 
chapter 2, both in terms of concentration and molar ratios, are in agreement with the 
suggested dysfunctional ECM turnover in the glaucomatous TM (97, 121). The second 
aqueous humour study led to the successful quantification of CHI3L1, FLRG, HGF, MIF, 
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p-selectin, and uteroglobin, of which only HGF and MIF had previously been measured 
in aqueous humour. 
 
Previous studies on aqueous humour composition predominantly considered 
changes in protein concentrations. The few studies that did consider correlations with 
clinical factors did so in a limited fashion. To expand on the information gained 
through analysing protein concentrations and detect subtler yet potentially relevant 
changes, we also included correlation studies with a range of POAG disease 
descriptors, including IOP, CDR, age, and PSD. Several statistically significant 
correlations were determined in both studies, highlighting specific proteins for 
further investigation in regard to TM physiology and dysfunction. Further research 
on these proteins may reveal useful biomarkers or novel drug targets and enhance 
our understanding of the mechanisms involved in disease onset or progression. 
 
Chapter 4 forms a first step in elucidating the relevance of one of these proteins, 
namely uteroglobin. Whilst no significant impact of uteroglobin on TM cell 
contraction was determined, possibly due to the cell model used, the chapter 
discusses four potential mechanisms by which uteroglobin may affect TM cell 
behaviour, namely cell contraction, phagocytosis, interaction with fibronectin, and 
ECM crosslinking (Figure 4.10). All of these processes influence aqueous humour 
outflow and thus warrant further investigation to determine if and how uteroglobin 
plays a role in their regulation. 
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5.3 STUDY LIMITATIONS 
The limitations of each study contained in this thesis have been discussed in the 
respective chapter discussions (chapters 2-4). In summary, the main limitations of 
the aqueous humour studies presented in chapters 2 and 3 are the potential influence 
of hypotensive medication on aqueous humour composition and the limited sample 
volume, which prevented quantification of more analytes for each patient sample. 
Furthermore, the studies would benefit from repeat measurements in a separate 
cohort of participants to confirm the findings. While the use of samples from cataract 
patients as a control is not ideal, collection of aqueous humour from healthy eyes 
would be unethical, due to the invasive procedure required. Cataract samples are 
commonly used as a control for aqueous humour studies (79, 80, 92, 93, 99), given its 
routine availability and the estimated minimal impact of a cataract on aqueous 
humour protein concentration. 
 
Many plausible reasons exist for the inconclusive results presented in chapter 4. It is 
possible that the cell strain used is not responsive to uteroglobin treatment and other 
TM cell strains should be tested to address this. The bioactivity of uteroglobin was not 
assessed, which presents an important limitation to this study. It is also possible that 
the contraction assay used is not sensitive enough to detect the effects of uteroglobin, 
thus requiring the use of alternative approaches to assess contraction. 
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5.4 FUTURE DIRECTIONS 
5.4.1 Improved trabecular meshwork cell models 
As discussed in chapter 4, it would be preferable to test aqueous humour proteins on 
TM cells derived from POAG patients. However, primary TM cells strains can only be 
maintained for a limited time frame (149), requiring isolation from new eyes on a 
regular basis, and culturing glaucomatous TM cells presents additional challenges. 
The use of a stem cell-derived model could overcome these limitations by providing a 
large resource of genetically-relevant cells. 
 
Patient-derived iPSCs present a promising avenue for in vitro disease modelling, as 
they can be differentiated into specific cell types of interest with a disease-relevant 
genetic background, which is particularly important for diseases that are genetically 
heterogenous and complex, as is the case with POAG. Disease modelling using iPSCs 
has been successfully used to study the molecular mechanisms underlying a variety 
of diseases, including neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson’s disease, and amyotrophic lateral sclerosis. Differentiation of iPSCs to 
different retinal cell types has also enhanced our understanding of several ocular 
diseases, including glaucoma, age-related macular degeneration, Best disease, and 
retinitis pigmentosa (reviewed in (310)). With regards to the work presented in this 
thesis, iPSCs offer the opportunity to study the effects of different factors on TM cell 
behaviour, both in a healthy and a glaucomatous setting, using respective donor cells. 
Further benefits of developing such a model include the ability to investigate disease-
relevant genetic mutations, use as a drug screening tool for personalized medicine 
and drug discovery, and development of patient-specific, cell-based therapy to 
overcome issues of graft rejection (311). 
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The TM develops from a cranial neural crest-derived structure known as the 
periocular mesenchyme (POM), which also gives rise to multiple other structures of 
the anterior segment, including the sclera, ciliary body, iris, Schlemm’s canal, and 
cornea (312). Several methods have been published for generating neural crest cells 
from pluripotent stem cells (313-317) and studies of anterior segment dysgeneses 
have highlighted key transcription factors involved in the normal development of the 
POM and TM, namely PAX6, PITX2, FOXC1, and LMX1B (318-320) (see Figure 5.1). 
Whilst functional TM-like cells have been successfully derived from iPSCs using 
primary TM cell-derived ECM and conditioned medium to drive differentiation (252), 
a defined differentiation protocol with known factors would be the preferred method, 
especially in view of later clinical use. Recently, a protocol for defined differentiation 
of pluripotent stem cells to POM was published, using TGF and wnt inhibitors to 
drive the expression of PITX2, FOXC1 and LMX1B (321). It remains to be determined 
what conditions are required to generate TM cells from POM, and whether these stem 
cell-derived POM cells are capable of differentiation to TM cells. It is likely that factors 
present in the aqueous humour are necessary for the final differentiation to TM, as 
aqueous humour has been shown to induce differentiation of resident adult stem cells 
in the TM (146). 
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Figure 5.1 Differentiation of pluripotent stem cells to trabecular meshwork and 
associated markers. Figure adapted from LJ Danderian. 
 
5.4.2 Further investigations of aqueous humour proteins 
It is unclear whether the altered protein concentrations in glaucomatous aqueous 
humour result from changes in the TM or other tissues located along the aqueous 
humour pathway, but it is likely both are involved, as some of the proteins quantified 
are expressed by TM cells, whereas others, such as uteroglobin, are not. It also 
remains to be determined whether these changes are a cause, a consequence, or part 
of a compensatory mechanism in TM dysfunction. The results from the aqueous 
humour studies suggest TIMPs, uteroglobin, HGF, and FLRG as candidates for further 
investigation in relation to TM physiology and dysfunction. Future directions in 
relation to uteroglobin have been discussed extensively in chapter 4. 
 
With regards to MMPs and TIMPs, the current literature focuses on MMPs and their 
impact on ECM turnover. However, given the significant increases in three out of four 
known TIMPs in glaucomatous aqueous humour shown in chapter 2 and the 
knowledge that TIMPs also possess MMP-independent functions (reviewed in (223)), 
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TIMPs should be investigated in their own right with respect to TM physiology. The 
potential anti-apoptotic effect of TIMPs on TM cell apoptosis is of particular interest, 
as discussed in chapter 2. Treatment of TM cells in vitro with recombinant TIMP1 may 
reduce susceptibility to apoptosis induction, as previously observed in Burkitt’s 
lymphoma cell lines (322). The use of a broad spectrum MMP inhibitor or inactivation 
of TIMP1’s MMP-inhibitory activity via chemical reduction and alkylation, would 
permit exclusion of any MMP involvement in the resistance to apoptosis. 
 
FLRG binds to members of the TGF superfamily, such as activin, myostatin, and 
BMP2, thereby blocking their interaction with cell surface receptors (246, 323, 324). 
The TM is thought to undergo a pathological calcification process with age, which is 
enhanced in POAG and induced by BMP2 (196, 325, 326). FLRG may therefore play a 
role in preventing calcification by inhibiting BMP2. Overexpression of BMP2 in TM 
cells in vitro increases calcification, as determined by alizarin red staining (227). If 
the above hypothesis is true, TM cells pre-treated with FLRG would be expected to 
show less calcification, unless FLRG interaction was blocked by an anti-FLRG antibody 
or a specific inhibitor. FLRG has also been shown to interact with fibronectin. Using 
hematopoietic UT-7 cells and primary human hematopoietic cells, enhanced cell 
adhesion to fibronectin was observed with increased FLRG concentrations (327). As 
fibronectin is abundant in the TM ECM, investigation of FLRG interaction with 
fibronectin may be of interest to TM physiology. Finally, follistatin, a BMP and activin 
inhibitor highly homologous to FLRG, is expressed by TM cells, and expression is 
upregulated by TGF-2 (239). Given the structural and functional similarities 
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between follistatin and FLRG, it is possible that TGF-2 may also regulate FLRG 
expression. 
 
HGF has been shown to enhance MMP activity in cultured endothelial cells (254). 
Treatment of perfused anterior segments with HGF may have a comparable effect to 
perfusion with MMPs, increasing aqueous humour outflow (101). In human 
keratinocytes, HGF inhibits UVB-induced apoptosis (328). Equally, HGF may protect 
TM cells from apoptosis, a process that has been suggested to be involved in TM cell 
loss (221, 222). Thus, treatment of TM cells in vitro with HGF followed by chemical 
induction of apoptosis may result in reduced levels of apoptosis. 
 
5.5 CONCLUSION 
In conclusion, the research findings presented in this thesis enhance our current 
understanding of aqueous humour imbalances in POAG, by providing quantitative 
measurements of several MMPs, TIMPs, growth factors, and cytokines. 
Comprehensive analysis of the data led to several significant correlations between 
these proteins and multiple disease descriptors, which may help to shed light on 
cellular processes relevant to POAG pathogenesis. Furthermore, analysis of 
MMP/TIMP ratios demonstrated imbalances in MMP inhibition in POAG aqueous 
humour, a process of known relevance to TM function. Finally, the research highlights 
uteroglobin as a potential protein of interest in TM dysfunction and discusses four 
distinct cellular processes that may be affected by uteroglobin, all of which impact on 
aqueous humour outflow. 
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APPENDICES 
 
Appendix 1 Calculation of TIMP and MMP molecular weights for stoichiometric 
analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein UniProtKB ID AAs MW (Da) 
TIMP1 P01033 24-207 20708.8 
TIMP2 P16035 27-220 21755.0 
TIMP3 P35625 24-211 21690.1 
TIMP4 Q99727 30-224 22441.8 
MMP1 P03956 20-469 51844.2 
MMP2 P08253 30-660 70975.7 
MMP3 P08254 18-477 52221.0 
MMP7 P09237 18-267 27934.6 
MMP8 P22894 21-467 51130.2 
MMP9 P14780 20-707 76370.5 
MMP12 P39900 17-470 52329.4 
MMP13 P45452 20-471 51680.2 
Molecular weight (MW) given in Daltons (Da) 
was calculated using the amino acid sequence 
(AAs) stated (signal peptide sequence 
removed), retrieved from the UniProt database.  
 Appendix 2 Correlation of measured analytes & MMP/TIMP ratios to CDR for POAG 
samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analyte/ratio rs p-value N 
MMP1 -0.080 0.724 22 
MMP1/TIMP1 -0.257 0.270 16 
MMP1/TIMP2 -0.151 0.549 18 
MMP1/TIMP3 -0.285 0.237 19 
MMP1/TIMP4 -0.365 0.122 16 
MMP3/TIMP1 -0.201 0.352 17 
MMP3/TIMP2 -0.086 0.725 19 
MMP3/TIMP3 -0.202 0.393 20 
MMP3/TIMP4 -0.359 0.128 16 
MMP9/TIMP3 -0.267 0.269 19 
MMP9/TIMP4 -0.046 0.756 16 
Correlation of analytes and MMP/TIMP 
ratios to CDR (optic cup-to-disc ratio) 
was determined using Spearman’s rank 
correlation. A p-value <0.05 was 
considered significant. Only 
correlations also shown in Table 2.5 are 
displayed. rs: Spearman correlation 
coefficient; N: number of correlation 
pairs 
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Appendix 3 Standard curve ranges of multiplex assays 
Analyte HGNC code Range 
Cataract 
detected/total  
POAG 
detected/total 
Angiopoietin-1 ANGPT1 127.5 - 30980 0/18 0/19 
Angiopoietin-2 ANGPT2 113.0 - 27450 0/18 0/19 
BMP2 BMP2 32.4 - 7860 0/18 0/19 
BMP4 BMP4 48.3 - 11730 0/18 0/19 
BMP9 GDF2 5.0 - 1200 0/18 0/19 
CCL27/CTACK CCL27 7.5 - 1830 0/18 0/19 
CHI3L1/YKL-40 CHI3L1 368.2 - 89460 18/18 19/19 
Collagen IV alpha 1 COL4A1 122.9 - 29860 1/18 1/19 
Cripto-1 CFC1 40.7 - 9900 0/18 0/19 
DcR3 TNFRSF6B 1031.2 - 250580 0/18 0/19 
EGF  EGF 17.8 - 4320 0/18 0/19 
Endoglin/CD105 ENG 463.4 - 112610 0/18 0/19 
Endothelin-1 EDN1 31.9 - 7760 0/18 0/19 
Epo EPO 456.8 - 111000 0/18 0/19 
FLRG FSTL3 961.6 - 233660 16/18 19/19 
Follistatin FST 2674.9 - 650000 0/18 0/19 
Growth Hormone GH1 76.1 - 18500 0/18 0/19 
HGF HGF 43.2 - 10500 9/18 18/19 
IGFBP-1 IGFBP1 163.3 - 39690 6/18 8/19 
IGFBP-3 IGFBP3 2824.7 - 686400 0/18 0/19 
IL-6 IL6 13.9 - 3370 0/18 0/19 
IL-9 IL9 3012.4 - 732000 0/18 0/19 
LIF LIF 68.1 - 16550 0/18 0/19 
MFG-E8 MFGE8 391.8 - 95200 2/18 1/19 
MIF MIF 781.9 - 190000 15/18 15/19 
P-Selectin SELP 223.3 - 54270 9/18 15/19 
Thrombospondin-2 THBS2 349.2 - 84860 0/18 0/19 
Uteroglobin SCGB1A1 30.5 - 7400 17/18 18/19 
VCAM-1 
VCAM1 
7440.7 - 
1808100 
6/18 8/19 
vWF-A2 VWF 97.1 - 23600 0/18 0/19 
HGNC: HUGO Gene Nomenclature Committee. Range: Concentration range of standard 
curve in pg/ml. POAG: Primary open-angle glaucoma. Analytes detected in more than 
50% of samples in at least one patient group are highlighted in bold and were further 
analysed (see Table 3.2, Table 3.3 and Table 3.4). 
 
 
 
 Appendix 4 Correlation of measured analytes to IOP for non-glaucomatous cataract 
and POAG samples 
 Cataract   POAG  
Analyte/ratio rs p-value N  rs p-value N 
CHI3L1 0.050 0.845 18  -0.416 0.076 19 
FLRG -0.040 0.826 16  -0.044 0.857 19 
HGF -0.417 0.236 9  -0.402 0.098 18 
MIF -0.167 0.480 15  -0.326 0.183 15 
P-selectin -0.369 0.275 9  -0.398 0.106 15 
Uteroglobin -0.379 0.113 17  -0.055 0.827 18 
Correlations of normalised analyte concentrations to intraocular 
pressure (IOP) were determined using Spearman’s rank 
correlation. Following correction for multiple testing using 
Bonferroni’s method, a p-value of <0.0017 was considered 
significant. rs: Spearman correlation coefficient; N: number of 
correlation pairs. 
 
 
 
Appendix 5 Correlation of measured analytes to CDR for non-glaucomatous cataract 
and POAG samples 
 Cataract  POAG 
Analyte rs p-value N  rs p-value N 
CHI3L1 -0.539 0.021 18  -0.004 0.988 19 
FLRG -0.249 0.224 16  -0.091 0.711 19 
HGF -0.292 0.310 9  -0.110 0.665 18 
MIF -0.213 0.322 15  -0.139 0.560 15 
P-selectin -0.588 0.635 9  -0.091 0.648 15 
Uteroglobin -0.191 0.325 17  -0.163 0.520 18 
Correlations of normalised analyte concentrations to cup-to-
disc ratio (CDR) were determined using Spearman’s rank 
correlation. Following correction for multiple testing using 
Bonferroni’s method, a p-value of <0.0017 was considered 
significant. rs: Spearman correlation coefficient; N: number of 
correlation pairs. 
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Appendix 6 Correlation of measured analytes to MD for non-glaucomatous cataract 
and POAG samples 
 Cataract   POAG  
Analyte/ratio rs p-value N  rs p-value N 
CHI3L1 0.100 0.950 5  0.187 0.541 13 
FLRG 0.400 0.750 4  -0.445 0.130 13 
HGF 0.500 >0.999 3  -0.252 0.430 12 
MIF 0.600 0.417 4  -0.050 0.912 9 
P-selectin N/A N/A 1  -0.119 0.716 12 
Uteroglobin -0.200 0.783 5  -0.336 0.287 12 
Correlations of normalised analyte concentrations to mean 
deviation (MD) were determined using Spearman’s rank 
correlation. Following correction for multiple testing using 
Bonferroni’s method, a p-value of <0.0017 was considered 
significant. rs: Spearman correlation coefficient; N: number of 
correlation pairs; N/A: not available. 
 
 
 
Appendix 7 Correlation of measured analytes to PSD for non-glaucomatous cataract 
and POAG samples 
 Cataract   POAG  
Analyte/ratio rs p-value N  rs p-value N 
CHI3L1 0.086 0.919 6  0.260 0.283 19 
FLRG 0.700 0.233 5  0.493 0.032 19 
HGF 1.000 0.333 3  0.536 0.022 18 
MIF -0.600 0.350 5  0.136 0.630 15 
P-selectin N/A N/A 2  0.186 0.504 15 
Uteroglobin -0.257 0.658 6  0.212 0.399 18 
Correlations of normalised analyte concentrations to 
Humphrey’s visual field pattern standard deviation (PSD) 
were determined using Spearman’s rank correlation. 
Following correction for multiple testing using Bonferroni’s 
method, a p-value of <0.0017 was considered significant. rs: 
Spearman correlation coefficient; N: number of correlation 
pairs; N/A: not available. 
 
 
 
 Appendix 8 TaqMan probes used for TM marker and housekeeper gene expression 
analysis 
Target symbol HGNC-approved name Reference (Thermo Fisher) 
AQP1 aquaporin 1 Hs01028916_m1 
CHI3L1 chitinase 3 like 1 Hs00609691_m1 
HPRT1 hypoxanthine 
phosphoribosyltransferase 1 
Hs99999909_m1 
MGP matrix GLA protein Hs00969490_m1 
MMP3 matrix metallopeptidase 3 Hs00968305_m1 
MYOC myocilin Hs00165345_m1 
TIMP2 TIMP metallopeptidase inhibitor 2 Hs00234278_m1 
 
 
 
Appendix 9 TaqMan probes used for gene expression analysis of HGF, uteroglobin, 
and their respective receptors. 
Target symbol HGNC-approved name Reference (Thermo Fisher) 
FPR2 formyl peptide receptor 2 Hs02759175_s1 
HGF hepatocyte growth factor Hs00300159_m1 
LMBR1L limb development membrane 
protein 1 like 
Hs00216545_m1 
MET MET proto-oncogene Hs01565576_m1 
UG secretoglobin family 1A member 
1 (SCGB1A1) 
Hs00171092_m1 
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Appendix 10 Primary antibodies used for immunocytofluorescence 
Target Type/Species Location Dilution 
Manufacturer and 
reference 
AQP1 polyclonal/rabbit intracellular 1:50 Santa Cruz 
Biotechnology, Inc.  
(Dallas, TX) 
Ref# sc-20810 
CHI3L1 polyclonal/rabbit intracellular 1:50 Santa Cruz 
Biotechnology, Inc.  
Ref# sc-98955 
MET monoclonal/rabbit extracellular 1:500 Cell Signaling 
Technology, Inc. 
Ref# 8198 
LMBR1L polyclonal/rabbit intracellular 1:200 Proteintech Group, Inc. 
(Rosemont, IL) 
Ref# 12154-1-AP 
 
 
 
Appendix 11 Secondary Antibody used for immunocytofluorescence 
Type Fluorophore Dilution 
Manufacturer and 
reference 
Anti-rabbit IgG (H+L), 
F(ab’)2 fragment 
Alexa Fluor 555 1:500 Cell Signaling 
Technology, Inc. 
Ref# 4413 
 
 
  
Appendix 12 Western blot of myocilin in pHTMC conditioned media with 
Dexamethasone (Dex) treatment. Conditioned media from pHTMCs in vitro was 
harvested after 3 or 5 days of exposure to vehicle control (0.1% ethanol), 100 nM, or 
500 nM Dex. No media replacement occurred during the treatment period. The 
conditioned media was analysed using 4-15% Mini-PROTEAN TGX Precast SDS-PAGE 
gels followed by Western blotting. Naïve media was run as a control (on a separate gel). 
The samples show a single band at the expected size of approx. 57 kDa, corresponding 
to monomeric myocilin. Samples from three separate Dex treatments were tested 
(n=3). 
 
